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Abstract 
Radiation therapy is one of the most common treatments for prostate cancer. 
Until the advent of image-guided radiation therapy (IGRT), the traditional method of 
setting up and verifying a patient’s positioning for radiation therapy treatment had been 
external skin marks and bony anatomy.  However, the prostate is known to move 
independently of external skin marks and surrounding pelvic bony anatomy. Daily 
IGRT now allows for correction and monitoring of this motion.  
 
This study investigated the relationship between patient obesity, measured by 
body mass index (BMI), an easily measured indicator of obesity, and prostate motion. 
The side effects of treatment and patient-reported QOL were also investigated for 
correlations with BMI and prostate motion. Prostate motion was assessed by 
measuring the displacement of fiducial markers implanted within the prostate during 
the radiation therapy treatment delivery in 130 prostate cancer patients. Interfractional 
motion was measured on daily imaging through pre-treatment cone-beam computed 
tomography (CBCT) and intrafractional motion measured using movie sequences 
captured on the electronic portal imaging device (EPID) during treatment delivery.  
Additionally, toxicity gradings by the radiation oncologists using the Common 
Terminology Criteria for Adverse Events (CTCAE) Version 4, and patient-reported 
QOL data were collected. QOL data were collected using the European Organisation 
for the Research and Treatment of Cancer validated core questionnaire (EORTC QLQ-
C30 V3) with the prostate cancer-specific module (QLQ-PR25) at simulation 
(baseline), every 2 weeks throughout treatment and at 3 month, 6 month and 12 month 
follow ups. 
 
There was no statistically significant relationship between the mean 
interfractional motion and BMI, except in the left-right (LR) direction (p=0.001) over 
the study population. For the mean interfractional motion for each BMI category, there 
was no statistical significance between any translations/rotations except LR (p=0.008), 
where there was a tendency for more lateral interfractional motion in the obese range, 
compared to both the underweight/normal and overweight categories.  
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For mean intrafractional motion, there was no significant relationship between 
the motion and BMI, except in the LR translation (p=0.049) and pitch rotation 
(p=0.011) over the study population. For each BMI category, there was no statistical 
significance (p>0.05) between any of the translations/rotations except LR (p=0.003) 
and pitch (p=0.007). There was a tendency for the prostate in obese patients to be more 
offset laterally, when compared to overweight patients. In overweight patients, there 
was a tendency for more of a posterior pitch rotation compared to obese patients.  
 
There was no significant correlation (p>0.05) between any of the QOL score 
changes and the BMI categories, as measured during treatment and in follow up.  
 
These findings support the evidence that IGRT is required to ensure accurate 
daily setup of the treatment of prostate cancer. While intrafractional motion is an 
important consideration, it is not influenced by BMI in a way that would allow the 
accurate prediction of intrafractional motion.  
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Chapter 1: Introduction 
Prostate cancer is one of the most common cancers in Australia, accounting  for 
29% of all cancer diagnoses, with a total of 18,560 males diagnosed in 2012 
(Australian Institute of Health and Welfare & Australasian Association of Cancer 
Registries, 2010; Australian Institute of Health and Welfare, 2012). In Queensland, 
3680 men were diagnosed with prostate cancer in 2007, accounting for 29% of all male 
cancers (Cancer Council Queensland, 2010). External Beam Radiation Therapy 
(EBRT) is one of the primary treatments of prostate cancer (Hayden, Martin, & 
Kneebone et al, 2010). The Radiation Oncology department of the Townsville Cancer 
Centre (TCC) treats approximately 150 to 200 patients with prostate cancer a year, 
accounting for 30 to 40% of the patients treated.  
 
Obesity is an increasing global epidemic, with potential implications in the 
treatment of prostate cancer. Body Mass Index (BMI) is an easily measured indicator 
of obesity. Seventy-six percent of Australian males aged 55 years or older are 
classified as overweight (BMI = 25.00 to 29.99 kg/m2) or obese (BMI ≥30.00 kg/m2) 
(National Health Survey: Summary of Results, 2007-2008, 2010). Recent findings 
indicate that there is an increased prostate cancer risk and incidence associated with 
overweight and obese patients (Fesinmeyer et al., 2010; Freedland et al., 2008). Obese 
men have significantly greater chance of dying of prostate cancer than non-obese men 
(Freedland & Aronson, 2004) and are approximately twice as likely to develop a high 
grade prostate cancer (Drenidis et al., 2009). Obesity is associated with a 98% increase 
in prostate cancer risk, after adjusting for lower Prostate-Specific Antigen (PSA) and 
a larger prostate size (Freedland et al., 2008). Additionally, overweight or obese 
prostate cancer patients are likely to be younger and have co-morbidities such as 
hypertension and diabetes compared to lower BMI groups (Kane et al., 2005).  
 
As the patient’s BMI increases, their suitability for surgical treatment (removal 
of the prostate gland through radical prostatectomy) decreases (Davies et al., 2008). In 
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those who are unsuitable for surgery, radiation therapy is the most common treatment 
option.  
 
As the radiation is designed to be tightly conformal around the prostate, 
consistency of patient set up is critical to ensure the prostate is treated as accurately as 
possible while minimising radiation exposure to normal tissues. Prostate motion out 
of the treatment beam either between or during daily treatment delivery potentially 
results in under-dosing of the planning target volume (PTV) of the prostate and 
overdosing of the surrounding normal tissue, resulting in increased side effects. 
 
Traditionally, patients are set up for treatment by aligning skin markers (usually 
tattoos) to a calibrated laser system, and positioning is checked by taking a 
radiographic image to ensure the treatment is being delivered in the same location as 
planned, relative to the patient’s pelvic bony anatomy.  Neither of these methods 
however take into account the actual position of the prostate within the pelvis on any 
given day. The insertion of fiducial markers into the prostate enables a more accurate 
daily set up to the prostate position.  
 
During EBRT, movement of the prostate may be detrimental to the optimal 
delivery of the radiation. Prostate motion potentially causes under-dosing of the 
planning target volume (PTV) and overdosing of the surrounding normal tissue 
resulting in increased side effects.  
 
There is, however, significantly greater set up variability in obese patients 
compared to less obese patients when treating with radiation therapy due largely to the 
mobility of external pelvic skin markers used to set up the patient on a daily basis 
(Ross & Patel, 2009). Overweight and obese patient groups show a significant 
difference in prostate shift on a daily basis (Wong et al., 2008). 
 
 
 Introduction 3 
1.1 CONTEXT 
There are two types of prostate motion which affect the accuracy of daily EBRT 
treatment.  
Inter-fractional motion is a variation in prostate position on a daily basis.  Setting 
the patient’s treatment to the same pelvic location each day may not correlate to the 
prostate location within the pelvis. This is corrected for by daily imaging to visualise 
three radio-opaque fiducial markers implanted within the prostate, and shifting the 
treatment couch based on their location.  
 
Intra-fractional motion is a variation in the prostate position during the delivery 
of each daily EBRT fraction, which including patient set up time and imaging, takes 
approximately 10 to 15 minutes. 
 
Two studies of note have investigated the correlation between BMI and prostate 
motion. Interfractional prostate motion in overweight (BMI 25-30) and obese patients 
(BMI >30) compared to a control group of BMI <25 showed motion in the 
anterior/posterior direction to be significantly greater in the overweight group than the 
control and obese groups; and motion in the left/right direction was significantly 
greater in the obese group (Wong et al., 2008). Intrafractional prostate motion assessed 
through pre- and post-treatment images was found to be less in the superior/inferior 
direction with patients with a higher BMI, however the study concluded that further 
investigation was warranted (Thompson et al., 2011). 
 
1.2 AIMS & OBJECTIVES 
1.2.1 Overall Aim 
To investigate the correlation between BMI and prostate displacement in terms 
of interfractional and intrafractional displacement over the course of a radiation 
therapy treatment.  
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1.2.2 Secondary Aims 
To investigate the relationship between BMI, intrafractional displacement, and 
the resulting acute and long term radiation therapy treatment side effects and patient 
quality of life.  
 
1.2.3 Hypothesis 
That the displacement, both inter- and intra-fractional, correlates significantly 
with the patient’s BMI.  
That the toxicity and quality of life correlates significantly with patient’s BMI.  
 
1.2.4 Endpoints 
Specific endpoints included: 
1. Measurement of inter-fractional prostate displacement, and investigation of 
the relationship to patient’s BMI;  
2. Measurement of intra-fractional prostate displacement, and investigation of 
the correlation to patient’s BMI;  
3. Correlation between patient’s BMI and toxicity gradings during treatment 
and at follow up; 
4. Correlation between patient BMI and self-reported quality of life during 
treatment and at follow up;  
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Figure 1.1. Main study components 
 
1.3 SIGNIFICANCE, SCOPE AND DEFINITIONS 
The effect of the patient's BMI on prostate motion over the course of an EBRT 
treatment had not been well documented. Interfractional prostate motion in overweight 
(BMI 25-30) and obese patients (BMI >30) compared to a control group (BMI <25) 
showed motion in the anterior/posterior direction was significantly greater in the 
overweight group than the control and obese groups; and motion in the left/right 
direction was significantly greater in the obese group (Wong et al., 2008). 
Intrafractional prostate motion assessed through pre- and post-treatment images was 
found to be less in the superior/inferior direction with patients with a higher BMI, 
however the authors concluded that further investigation was warranted (Thompson et 
al., 2011).  
 
By gaining an understanding of the effect of BMI on prostate motion, the 
development and implementation of treatment protocols based on BMI may benefit 
prostate cancer patients presenting for radiation therapy by increasing accuracy of 
treatment. Should there be a correlation between prostate motion and BMI, treatment 
margins may be adjusted according to patient’s BMI to ensure that the prostate motion 
is accounted for more accurately. Increased treatment accuracy increases tumour 
BMI
Toxicity 
& QOL
Prostate 
Motion
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control probability because the dose can be escalated while avoiding radiation delivery 
to healthy tissue with associated side effects. Dose escalation has been found to 
improve biochemical control (Dearnaley et al., 2007; Gauthier et al., 2009; Martin et 
al., 2009; Peeters et al., 2005).  With the ever increasing burden of both prostate cancer 
and obesity, the investigation into the correlation between BMI and prostate motion is 
important to ensure accurate delivery of radiation therapy.  
 
Understanding intra-fractional prostate motion is of critical importance with 
advances in radiation therapy, particularly in treatment delivery including intensity 
modulated radiation therapy (IMRT) delivery, volumetric modulated arc therapy 
(VMAT), adaptive radiation therapy and hypo-fractionated treatment schedules. Many 
of these treatments aim to deliver a highly conformal and targeted dose, the beneficial 
effect of which is diminished should there be significant prostate motion. Similarly, 
delivering a higher dose per fraction should be approached with caution if there is 
significant prostate motion during treatment delivery.  
 
This study’s research question arose through both clinical observations and a 
pilot study at TCC, in which greater inter-fractional prostate motion was measured in 
the obese patients. While this small study of 20 patients was not statistically powered, 
it warranted further investigation.  
 
1.4 THESIS OUTLINE 
Chapter 2 provides a background of treatment of prostate cancer with radiation 
therapy, and the problem of inter- and intra-fractional prostate motion in this treatment. 
This chapter provides a review of the current literature, with particular focus on IGRT 
in the treatment of prostate cancer.  
Chapter 3 details the research design and methodology employed. It details the 
collection and analysis of interfractional data, intrafractional data, toxicities and 
patient quality of life.  
 Introduction 7 
Chapter 4 presents the results of the study, including patient demographics; inter- 
and intra-user measurement results; inter- and intrafractional motion results for the 
study population and each BMI category; and toxicity and QOL results.  
Chapter 5 discusses and analyses the results presented in the previous chapter, 
applying them to the clinical setting Inter- and intrafractional results are contrasted and 
compared to published data. Potential future studies are identified.  
The thesis is concluded in Chapter 6, with recommendations for clinical focus 
and future study.  
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Chapter 2: Background & 
Literature Review 
2.1 RADIATION THERAPY TO THE PROSTATE: A HISTORY 
There have been many advances in the use of radiation therapy in the treatment 
of prostate cancer, as summarised in Figure 2.1. The need for escalated dose to 
improve cure rates necessitated more conformal and modulated treatment deliveries to 
ensure reduced toxicities.  
 
 
Figure 2.1. Prostate radiation therapy history and future directions summary 
 
2.1.1 Whole pelvic irradiation 
Standard EBRT in the mid-1990s involved the prostate being treated up to 66Gy, 
with the treatment fields encompassing a larger volume around the prostate, close to 
the whole pelvis region (Duchesne, 2001). This larger safety margin meant that inter- 
and intra-fraction motion was not as great a concern, as the prostate was still expected 
to be encompassed within the treatment field. However,  treating a larger area meant 
more surrounding critical tissue (bowel, femoral heads and necks, and bladder) was 
included within the treatment fields, limiting the dose that could be safely delivered 
without resulting in considerable treatment toxicities (Duchesne, 2001). The 
development of multi-leaf collimators (MLCs) to custom-shape each treatment field 
in the late 1960s and subsequent integration in modern-day linacs in the mid to late 
1990s led to more conformal treatments.  
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2.1.2 3D Conformal Radiation Therapy 
The introduction of 3D Conformal Radiation Therapy (3DCRT) allowed for 
improved dosimetry in the treatment of prostate cancer. Using CT data to plan 
treatment meant that critical structures could be outlined and dose-volume histograms 
(DVHs) evaluated. The additional information provided meant critical structures could 
be kept under tolerance, allowing dose to be escalated to 74Gy while keeping the beam 
arrangement of anterior, posterior and two laterals (Perez, Michalski, Mansur, & 
Lockett, 2002). The emergence of evidence suggesting a benefit from further dose 
escalation to 78Gy led to the development of different beam arrangements 
(D’Ambrosio et al., 2008; Duchesne, 2001). The 3DCRT beam arrangement currently 
utilised within our department is shown in Figure 2.2 (a).   Laterals or posterior 
obliques, anterior obliques and a direct anterior beam can, in the majority of cases, be 
delivered successfully without exceeding critical tissue tolerances.  
 
2.1.3 IMRT & VMAT 
Further advances in both planning and treatment delivery have led to modulated 
delivery of EBRT. One of the first clinical experiences by Zelefsky et al (2000), 
reported on the efficacy of IMRT compared to 3DCRT for prostate EBRT. The trial 
results demonstrated dose conformality and tumour coverage improvements, reduced 
dose to surrounding structures and reduced combined grade 1 and 2 rectal toxicities in 
the IMRT arm (Zelefsky et al., 2000). 
 
IMRT and VMAT show promise for dose optimisation and critical structure 
sparing, as demonstrated in Figure 2.2., however these techniques require greater 
resources at every stage than EBRT, including planning, quality assurance and 
treatment delivery. A greater amount of contouring is required at planning. Each plan 
requires measurement-based quality assurance on the treatment linac, costing both 
machine and physicist time. Additionally, longer treatment times are required for 
IMRT delivery, due to the delivery of multiple segments. VMAT, however, has 
allowed for more efficient delivery of intensity modulated plans.  
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The steeper dose gradients achieved in IMRT and VMAT increase the 
importance of accounting for intrafraction motion, as prostate motion beyond the PTV 
results in a more significant reduction in dose, compared to less conformal techniques 
where the dose does not conform as closely to the target.  
 
 
Figure 2.2. IMRT (b) and VMAT (c) provide more conformal treatment than 
3DCRT (a) in the treatment of prostate cancer 
 
While IMRT and VMAT are promising in dose delivery and critical structure 
sparing, the planning and checking of each patient’s treatment requires greater 
resources than that of EBRT (Bauman, Rumble, Chen, Loblaw, & Warde, 2012). 
 
Not all departments currently offer IMRT or VMAT prostate treatments. A 2010 
survey of Australian centres found that while IMRT-capable equipment was available 
in 97% of centres, only 35 centres (71%) were offering IMRT treatment and accounted 
for only 6.5% of all radiation therapy treatments delivered (Radiation Oncology 
Tripartite Committee, 2012). Current Australian and New Zealand consensus 
guidelines advocate for IMRT when dose constraints are unachievable with 3DCRT 
(Hayden et al., 2010). 
 
c 
b a 
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2.1.4 Hypofractionation 
The efficacy of hypofractionation of EBRT is currently being investigated. 
Hypofractionation involves the delivery of a higher dose per fraction (2.1-3.5Gy), 
abbreviating the whole course of treatment (Zaorsky, Ohri, Showalter, Dicker, & Den, 
2013). Hypofractionation takes advantage of the reported α/β ratio of 1.5Gy for the 
prostate and for the rectum 4-6Gy (Tree, Ostler, & van As, 2014).  As the α/β ratio is 
lower for the prostate cancer than surrounding structures, there is radiobiological 
advantage in a higher dose per fraction. This may result in improved tumour control 
probability while decreasing normal tissue complication probability.  Current 
regimens which have been studied include: 52.5Gy/20#; 55Gy/20#; 62Gy/20#; 
70.2Gy/26#; 72Gy/30# (Zaorsky et al., 2013).   
 
Stereotactic ablative radiotherapy (SABR) is also being studied. A recent report 
of 35Gy/5# delivered once a week over 29 days was demonstrated to be well tolerated 
by the patients with good biochemical control, however long-term follow up is still 
ongoing (Loblaw et al., 2013).  
 
Again, intrafractional motion is of greater concern with the higher fractional 
dose delivery (Adamson, Wu, & Yan, 2010; D’Ambrosio et al., 2012). The higher the 
dose delivered while the target is moving, the greater the potential for geometric miss 
of the prostate and increased dose to surrounding tissues. A repositioning action 
threshold in which the treatment is interrupted and the motion corrected for is enforced 
in many hypofractionated regimes. One reported example of a repositioning action is 
if there is 3 mm displacement in any direction for longer than 30 seconds, treatment is 
interrupted and corrected (Curtis et al., 2013). The ability to enforce this action 
threshold however requires continuous localisation monitoring capabilities such as 
electromagnetic beacons, which are discussed further in Section 2.2.5.  
 
2.1.5 Other treatments 
Other radiation treatments for prostate cancer include brachytherapy, 
tomotherapy and proton therapy, however these modalities are beyond the scope of 
this project.  
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2.2 IGRT PRINCIPLES AND TECHNIQUES/TECHNOLOGIES  
Image Guided Radiotherapy (IGRT) has provided further advancements to 
treatment. Geometric misses without IGRT have been shown to significantly reduce 
biochemical and local control, due largely to rectal wall changes on a day to day basis 
(De Crevoisier et al., 2005; Heemsbergen et al., 2007).  
 
Current Australian and New Zealand consensus is: “Image guided radiation 
therapy (IGRT) using daily pre-treatment verification of prostate position is 
recommended when delivering definitive external beam radiotherapy for prostate 
cancer” (Hayden et al., 2010). The American Society for Therapeutic Radiology and 
Oncology (ASTRO) and American College of Radiology (ACR) IGRT guidelines 
(Potters et al., 2010) also echo current Australian recommendations. Both the 
Australian and American guidelines stress the importance of strict quality assurance 
protocols, and the consideration of the benefits or disadvantages of the delivery of 
additional radiation dose, depending on which IGRT method is utilised (Hayden et al., 
2010; Potters et al., 2010).  
 
 
2.2.1 Megavoltage (MV) portal images  
Historically, a pair of anterior and lateral portal images were taken and the 
alignment of the treatment field was assessed against bony anatomy such as the pubic 
symphysis. Orthogonal films were adequate for larger fields encompassing a greater 
area around the prostate, however as fields became increasingly conformal, it was 
shown that the bony anatomy did not necessarily correspond to the prostate position 
(O’Daniel, Dong, Zhang, et al., 2006). Therefore, a surrogate for prostate position, 
visible across the different imaging modalities was required.  
 
 
2.2.2 Fiducial Markers 
Fiducial markers (FMs) have been widely implemented as the image-guidance 
method of choice for many radiation oncology centres. The fiducial markers are small 
seeds, manufactured from a variety of materials, which are implanted into the prostate 
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under ultrasound guidance. The FMs (CIVCO Medical Solutions, Iowa USA) utilised 
in this study were 99% gold, measuring 3mm by 1mm. Ideally, three markers are 
implanted in the prostate: at the base, the ipsilateral apex and the contralateral mid-
gland. They are implanted laterally to avoid the urethra (Shinohara & Roach, 2008). 
While it is recommended that three fiducial markers are implanted in a triangular 
arrangement (Linden et al., 2009; Shinohara & Roach, 2008), it has been demonstrated 
that even a single marker is more accurate than bony anatomy. Kudchadker et al.  
(2009) found that using a single marker did not account for prostate deformation 
however, which is best determined by at least two markers. 
 
The efficacy of fiducial markers as a prostate surrogate is well documented 
(Chung et al., 2004; Schallenkamp, Herman, Kruse, & Pisansky, 2005; Van Der Heide 
et al., 2006). Schallenkemp et al., (2005) found significant difference in prostate 
position when comparing FMs to bony matching, with prostate displacements of up to 
15 mm in the right-left (RL) axis, 16 mm in the anterior-posterior (AP) axis, and 9 mm 
in the superior-posterior (SI) axis.  
 
While 2D planar images can be acquired and assessed, with correction applied 
as required, the 2D images do not provide additional information of surrounding 
tissues and critical structures, as discussed further in Section 2.2.4.  
 
The insertion of fiducial markers is not always viable. For example, if the patient 
is highly dependent upon certain blood thinning medications (such as Warfarin) and 
cannot safely cease this for the time around the implant, then implantation is 
contraindicated. In these cases, prostatic calcifications have been found to be a viable 
alternative, should the patient have them present. In a feasibility study, it was found 
that 35% of prostate patients presenting for radiation therapy treatment had suitable 
calcifications for IGRT (Zeng et al., 2008). Hanna et al., (2012) compared central 
prostatic calcifications to fiducial markers in 10 patients and found that there was no 
significant difference between the use of FMs and the calcifications. 
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2.2.3 CT on rails 
A CT on rails set up includes a diagnostic-quality CT scanner in the treatment 
bunker, with the bore in line with the treatment couch. Upon initial setup, a CT scan 
is acquired for IGRT purposes, and the patient is repositioned under the linac with the 
isocentre corrections applied. The main advantage is the high quality images produced 
by the CT scanner (Owen et al., 2011; Wong et al., 2005). Disadvantages include high 
capital expenditure, the amount of physical space required in the treatment bunker, and 
the potential for patient movement as the couch is moved from the CT scanner to the 
treatment linac, and isocentre adjustments are made (Bylund et al., 2008; Owen et al., 
2011; Wong et al., 2005).  
 
Owen et al., (2010) in comparing CT on rails to Electronic Portal Images (EPIs), 
and kilovoltage (kV) CBCTs generated on the linac itself, concluded that a single 
isocentre IGRT solution is preferable to reduce the potential for patient motion during 
couch movement from CT scanner to linac.  
 
2.2.4 CBCT 
Most modern linacs are now equipped with kV or MV CBCT capabilities, 
increasing the use of CBCT in prostate EBRT to produce 3D volumetric imaging. The 
CBCT may be acquired and accessed with or without fiducial markers, however the 
poor image quality makes soft tissue definition difficult and therefore fiducial markers 
are often preferred.  Fiducial markers do cause artefacts on the CBCT, however, and 
there are the associated costs of implantation.  
 
kV CBCT 
The image quality of the kV CBCT acquired does not rival that of a diagnostic 
CT, and without the use of fiducial markers in conjunction with the CBCT, it can be 
difficult for the treatment staff to clearly demarcate the prostate from surrounding 
tissue.  Figure 2.3 shows a typical example of this ambiguity.  
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Figure 2.3. Soft tissues definition achieved with kV CBCT, with artefact from 
fiducial markers. Structure contours (red=prostate; cyan=seminal vesicles; 
yellow=bladder; purple=rectum) are displayed.  
 
 The combination of both CBCT and FMs provides additional information when 
compared with 2D planar images, or CBCT alone. The fiducial markers allow for 
definitive prostate correction and the CBCT enables the assessment of bladder and 
rectal filling, and can guide the treatment staff’s decision to continue with treatment 
delivery or to take decisive action such as requesting the patient releases bowel gas or 
increases bladder filling prior to treatment. There are currently no internationally 
accepted thresholds for surrounding tissue volumes, and so intervention is therefore at 
the discretion of the treatment radiation therapists.  A consideration for deparemtns in 
the developing of their IGRT protocol is the additional dose delivered in acquiring 
CBCT compared to planar imaging (Table 2.1).  
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MV CBCT 
Similarly, the MV CBCT has poorer image quality than the diagnostic CT and 
the kV CBCT. The main advantage of the MV CBCT over the kV CBCT is that dose 
can be accounted for in planning (Bylund et al., 2008).  
 
2.2.5 Electromagnetic tracking 
Perhaps one of the most promising IGRT techniques, electromagnetic tracking 
utilises radiotransponders implanted into the prostate instead of gold fiducial markers. 
This allows real-time, instantaneous feedback to the treatment staff about the prostate 
position during treatment delivery (Litzenberg et al., 2007; Rajendran et al., 2010; 
Shah, Kupelian, Willoughby, Langen, & Meeks, 2011). Electromagnetic tracking has 
been demonstrated to increase PTV coverage while decreasing overdose to 
surrounding tissues, particularly the rectal wall (Rajendran et al., 2010). 
 
Another advantage of electromagnetic tracking is that no additional dose is 
required (Litzenberg et al., 2007). However, high capital costs are required to 
implement this technique, with the installation of detectors required in the treatment 
bunker. Increased ongoing costs are a consideration, as the beacons are currently 
approximately seven times more expensive than gold fiducial markers. 
 
A limitation of an electromagnetic system is the distance required between the 
anterior body surface and the prostate: it must be between 17 and 23cm to allow for 
localisation and tracking (Rajendran et al., 2010). This  limitation may preclude its use 
in some of the extreme low and high BMI patients from treatment in the supine 
position, however can be successfully tracked in the prone position in a majority of 
patients (Bittner et al., 2010).  
 
 
2.2.6 Ultrasound: Transabdominal 
 
The main advantage of the transabdominal ultrasound technique is, as with 
electromagnetic tracking, no additional radiation dose is required. It also does not 
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require implantation of markers/beacons, thus saving the patient from an invasive 
procedure and an additional visit to the hospital.  
One of the main criticisms of this technique is the inter-user variability. The 
transabdominal image can be interpreted subjectively by the operator, compounded 
when comparing two different modalities, such as planning CT to Ultrasound (USS). 
Extensive training of the treating team is required to limit this variability and 
subjectivity.    Langen et al., (2003) demonstrated an inter-user variability of up to 7 
mm, interestingly with an urologist and a radiation oncologist performing the matches. 
Similarly, Robinson et al., (2012) found mean differences of up to 8.7 mm when 
comparing CT to the Clarity 3D USS system.  
 
Another criticism is that the transducer itself introduces motion of the prostate 
through the pressure against the skin required to detect the prostate.  The prostate may 
also move on removal of the transducer due to the release in pressure (Fargier-Voiron 
et al., 2013; Hu et al., 2010; Pinkawa et al., 2006; Scarbrough et al., 2006). A 3 to 4 
mm discrepancy due to this issue has been reported (Fargier-Voiron et al., 2013; 
Pinkawa et al., 2006) and this criticism lead to the development of perineal USS.  
 
When comparing transabdominal USS to FMs, Scarbrough et al., (2006) 
concluded a significant discrepancy, with greater systematic and random errors in USS 
displacement, and a difference of up to 8.8 mm (p < 0.0001) between the two methods.  
 
2.2.7 Ultrasound: Perineal 
Unlike the transabdominal USS, the perineal technique has the transponder 
probe placed against the perineum throughout CT simulation, treatment set up and 
treatment delivery, thus eliminating the differing pressures noted in transabdominal 
USS(Abramowitz et al., 2012). Patient comfort and compliance has yet to be reported 
within the literature, and will be a vital component to continued uptake and success of 
this technology.  
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2.2.8 Comparison of IGRT Techniques 
Table 2.1 provides an overview of the different techniques for the measurement of the prostate position, as discussed in Section 2.2. 
Table 2.1 
Comparison and Critique of IGRT Techniques 
Imaging 
Technique 
Efficacy & Efficiency Cost/ Capital Expenditure Additional Dose 
Intra-fractional 
monitoring 
capabilities  
Patient Comfort and 
Compliance 
 MV portal images 
– bony anatomy  
Medium quality for assessing bony anatomy, 
however this is known to not reflect prostate 
position. Soft tissue definition very low 
quality, with no clear prostate demarcation.  
Low – EPIDs capabilities 
standard on most modern 
linacs 
Dependent upon imaging 
schedule. Each 
stereoscopic pair = 4-8 
MU.  
 
Weekly (8) = 32 - 64MU 
(~0.32 – 0.64Gy) 
Daily (39) = 156-312 
(~1.56-3.12Gy) 
Nil Nil issues 
Fiducial Markers 
Act as surrogate for prostate. Clearly visible 
on MV, kV and CBCT imaging.  
Dependent upon material of 
markers 
 
Cost of Implantation session  
Dependent upon type of 
imaging (MV, CBCT or 
kV planar).  
Offline with movie 
captures 
Some patients may have 
concerns/nerves about 
implantation – a few refuse 
the procedure or cannot 
tolerate it.  
CBCT 
Lower quality kV images – can be difficult 
to demarcate the prostate from the 
surrounding tissue. Fiducial markers may be 
used as surrogate. 
Low – CBCT capabilities 
standard on most modern 
linacs 
Dependent upon vendor 
and scan protocols (full 
360° scan vs partial scan, 
filters and kV & mAs 
settings). 
 
Protocol utilised in this 
study = 28.5mGy per scan 
Only during CBCT 
acquisition – not 
easily assessed with 
current linac 
capabilities. May be 
seen as artefact on 
scan.  
Minimal issues – may add 
another few minutes to time 
on treatment couch 
CT on rails 
High quality MV images  High – cost of CT on rails, 
installation, potential bunker 
modifications to create 
adequate physical space. 
 Only during CT 
acquisition – may be 
seen as artefact on 
scan.  
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Imaging 
Technique 
Efficacy & Efficiency Cost/ Capital Expenditure Additional Dose 
Intra-fractional 
monitoring 
capabilities  
Patient Comfort and 
Compliance 
Electromagnetic 
tracking 
Acts as surrogate for prostate, giving real-
time feedback on position. Does not provide 
information on surrounding tissues, such as 
bladder and bowel filling, however with 
real-time correction, this concern is lessened.  
Capital: US$400,000 
Consumables: $700/patient 
for beacons (Personal 
Communication, March 2014) 
 
Other consumables of 
implantation – similar to 
fiducials 
Nil Real-time 
information fed back 
to treatment staff. 
Option to set action-
threshold for machine 
to switch off if 
prostate moves 
outside of set 
tolerance.  
Some patients may have 
concerns/nerves about 
implantation – a few refuse 
the procedure or cannot 
tolerate it. 
USS: Transabdo 
Medium quality images of soft tissues, 
including prostate and bladder. Quality 
dependent upon patient’s size, with greater 
adiposity in pelvis decreasing image quality.  
Cost of USS & software 
 
 
Nil  Anecdotal evidence of 
pressure on bladder causing 
discomfort.  
USS: 
Transperineal 
Medium quality images of soft tissues, 
including prostate and bladder. Quality not 
as dependent upon patient’s size, with probe 
against perineum.  
Cost of USS & software 
 
Additional software upgrade 
to enable intrafractional 
detection 
Nil Possible with 
software upgrade.  
Not reported on 
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2.3 INTER AND INTRAFRACTIONAL MOTION 
 
2.3.1 External Skin Marks 
It is well established that setting the patient up to external skin marks such as 
tattoos does not necessarily correlate with the internal prostate position (Mangar et al., 
2005; O’Daniel, Dong, & Zhang, 2006; Schallenkamp et al., 2005). There is greater 
set up variability in obese patients when treating with radiation therapy due largely to 
the mobility of external pelvic skin markers used to set up the patient on a daily basis 
(Ross & Patel, 2009). 
 
2.3.2 Bladder and Rectal Influences 
The influence of the volume, shape and contents of the bladder and rectum on 
the position of the prostate is well documented. Current treatment protocols often 
include specific bladder and bowel regimens, that is, specific emptying or filling 
instructions.  
 
Peristalsis 
Peristalsis is one of the greatest causes of prostate motion, both interfractional 
and intrafractional (Ghilezan et al., 2005; Nichol et al., 2010). The presence of faeces 
and/or gas can directly impact the position of the prostate, and the movement of faeces 
and gas through the rectum can cause sudden and rapid prostate motion.  
 
In monitoring intrafraction motion on cine-MRI, three rectal wall motions were 
described by Nichol et al., (2010): transient due to the antegrade or retrograde 
movement of gas past the prostate or by peristalsis when faecal matter was present; 
persistent due to faecal matter, gas or both descending from above the prostate through 
the rectum; and drifting motion due to gradual bladder filling. Despite patients being 
on a milk of magnesia laxative protocol and an anti-flatulent diet, movements of 
greater than 3mm were measured in 12% of the treatments observed and were 
attributed to 49% transient, 31% persistent and 20% drifting motion (Nichol et al., 
2010). 
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Endorectal balloons, a catheter inserted into the rectum and inflated for daily 
treatment, has previously been found to immobilize the prostate and reduce 
intrafractional motion (Both et al., 2011; Wachter et al., 2002). However, it is argued 
that for the cost of patient discomfort,  the benefit of the endorectal balloons is not 
necessarily justified, with findings that the use of the balloon did not statistically 
significantly reduce motion (Hung, Garzotto, & Kaurin, 2011).  
 
A significantly higher incidence of biochemical failure (p = 0.0009) amongst 
patients with distended rectums when no daily IGRT protocol was followed was 
reported by de Crevoisier et al., (2005). The authors hypothesised that caused by 
geographical miss due to inter- and intrafractional prostate motion from changes in 
rectal shape/volume (de Crevoisier et al., 2005). This was supported by Heemsbergen 
et al., (2007).  
 
Bladder volume and filling 
Adamson and Wu (2009) found a weak correlation between intrafractional 
bladder filling and a posterior drift of the prostate, but only when there was little or no 
rectal gas present. This was established through pre- and post- CBCT imaging, and the 
authors argue that because the weak correlation was with the percentage bladder 
volume change rather than the initial bladder volume, it would be difficult to efficiently 
quantify this in an online setting. Many departmental protocols require a comfortably 
full bladder for treatment. This may cause motion of the prostate due to the patient’s 
muscle tension required to hold their bladder (Langen & Jones, 2001).   
 
 
2.3.3 Respiratory motion 
In comparing prostate motion through electromagnetic transponders in the prone 
and supine positions, respiratory motion was found to contribute to the prone 
positioning motion in addition to the transient and drift prostate motions evident in the 
supine position (Shah et al., 2011). The respiratory motion was theorised to be due to 
increased abdominal pressure in the prone position. This supports the work of 
Nakamura et al., (2010), who reports a mean displacement due to respiratory motion 
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of 3.1 ± 1.1 mm in the prone position compared to 1.6 ± 0.1 mm in the supine position, 
using cine-MRI imaging.  
2.3.4 Intra-abdominal Pressure 
A consideration of a larger patient’s body habitus is the potentially increased 
abdominal and pelvic pressure placed on the treatment area. Rosewall et al., (2008) 
compared two abdominal compression methods (Vaclock (MedTec. Orange City, IA) 
and Bodyfix (Medical Intelligence. Schwabmunchen, Germany)), measuring both 
inter- and intra-fractional prostate motion. It was concluded that neither compression 
method influenced inter- or intra-fractional motion; however it is important to note 
that BMI or obesity characteristics were not reported.  
 
2.4 TOXICITIES 
 
The toxicities associated with the delivery of external beam radiation therapy are 
well established, based on the Quantitative Analysis of Normal Tissue Effects in the 
Clinic (QUANTEC) (Bentzen et al., 2010; Marks et al., 2010). In order to deliver an 
adequate dose to the prostate, surrounding healthy tissues are also irradiated. 
Surrounding structures and associated toxicities are listed in Table 2.2.  
Table 2.2 
Pelvic Structures and Associated Acute and Late Toxicities 
Structure Associated Toxicities  
Acute Late 
Rectum  Diarrhoea 
Tenesmus 
Rectal bleeding 
Diarrhoea 
Rectal bleeding 
Proctitis 
Rectal Incontinence  
Bladder Dysuria 
Frequency 
Retention 
Haematuria 
Incontinence 
Dysuria 
Frequency/Urgency 
Retention 
Haematuria 
Incontinence 
Urethral Stricture 
Cystitis  
Penile bulb Erectile dysfunction Erectile dysfunction 
Femoral Heads and Necks  - Fractures 
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2.4.1 Burden of Toxicities 
These treatment related toxicities are often compounded by the patient’s age, 
medical history, and concurrent treatments such as hormonal therapy. Limitations on 
dose to these critical structures to limit toxicities are guided by QUANTEC (Michalski, 
Gay, Jackson, Tucker, & Deasy, 2010; Roach et al., 2010; Viswanathan, Yorke, 
Marks, Eifel, & Shipley, 2010).  
 
Prostate cancer is more common in older men, with the risk of being diagnosed 
with prostate cancer of 1 in 8 for Australian men under the age of 75, increasing to 1 
in 6 for Australian men over the age of 85 (Australian Institute of Health and Welfare, 
2012). This age demographic increases the likelihood of existing medical conditions 
and co-morbidities that may exacerbate the toxicity of radiation therapy. Conditions 
of particular concern are diabetes and previous surgery to the pelvis (Fiorino, 
Valdagni, Rancati, & Sanguineti, 2009).    
 
Patients with intermediate or high-risk prostate cancer generally receive 
hormonal therapy as part of their treatment, which can contribute to or increase their 
toxicity, including hot flushes, loss of libido/erections, moodiness, fatigue, weight gain 
and breast tenderness (Budäus et al., 2012).  
 
With increasing life expectancy, the burden of late toxicities increases in prostate 
cancer survivors. The symptoms and treatment of late toxicities such as rectal bleeding 
and proctitis, and urinary and rectal incontinence increases cost of medical care, 
demand on resources and affects patient quality of life. IGRT has been shown to 
decrease toxicities, including rectal morbidity (Pearlstein & Chen, 2013; Singh et al., 
2013).  
 
The most common late rectal toxicity is rectal bleeding. This is usually mild and 
rarely results in serious consequences, but if particularly bothersome and reducing 
quality of life, it may be treated either with hyperbaric oxygen therapy or endoscopic 
cautery/ablation. Currently, 5-20% of prostate cancer patients may undergo hyperbaric 
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oxygen therapy for the treatment of  late rectal toxicities including proctitis and cystitis 
(Mayer et al., 2001; Oliai et al., 2012; Oscarsson, Arnell, Lodding, Ricksten, & 
Seeman-Lodding, 2013).  Hyperbaric oxygen therapy requires access to specialised 
facilities, and is expensive (Theis, Sripadam, Ramani, & Lal, 2010). There is a risk of 
rectal ulceration due to the more invasive nature of endoscopic ablation on the rectal 
mucosa (Sarin & Safar, 2013).  
 
While substantial long-term data on late treatment toxicities are still forthcoming 
for IGRT practices, emerging data reveals improved rectal symptoms when comparing 
IGRT to non-IGRT regimes, despite the IGRT patients having greater dose delivered 
to larger volumes of rectum. (Singh et al., 2013).  
 
2.5 QOL 
 
The burden of both acute and late toxicities on the patient can be significant. The 
negative impact from such toxicities can influence the patient’s social and emotional 
wellbeing and quality of life, as well as their physical quality of life.  Again, a patient’s 
quality of life may be negatively affected by neo-adjuvant and/or concurrent 
treatments such as hormonal therapies (Schaake et al., 2013; Wahlgren, Levitt, 
Kowalski, Nilsson, & Brandberg, 2011).  
 
 
2.6 OBESITY  
Obesity within the developed world has risen drastically over the past two 
decades, with adult obesity nearly doubling since 1980 (World Health Organisation, 
2013). Globally, obesity is the fifth leading risk for death, and a great proportion of 
the world population (65%) live in an area where obesity is a greater risk than 
malnutrition (World Health Organisation, 2013).  
 
A telephonic survey study of “Baby Boomers” (born in 1946 to 1964, one of the 
generations heavily represented in the prostate cancer population) conducted in South 
Australia revealed a significant increase in obesity from 2002 to 2007, however, it 
 Background & Literature Review 25 
should be noted that this was a self-reported survey (Hugo, Taylor, & Dalgrande, 
2008). 
During radiation therapy treatment, it has been shown that there is an increase in 
acute genitourinary toxicity for patients with a BMI of greater than 30 (Showalter et 
al., 2009). Ly et al., (2010) reported a significant reduction in treatment effectiveness 
when comparing normal vs. overweight and normal vs. obese men but not overweight 
vs. obese men. 
 
2.6.1 Controversies in BMI 
The use of BMI as an indicator of obesity is contentious within the health 
community, despite its wide use. One of the main arguments against is the fact that a 
change in weight, and therefore BMI, does not necessarily reflect a change in obesity 
– particularly when exercise is proven to increase skeletal muscle mass (Green, 2009). 
Alternative measures include waist circumference, hip-to-waist ratio, skin folds or 
body fat composition (Frankenfield, Rowe, Cooney, Smith, & Becker, 2001; González 
Jiménez, 2013), however these may require additional measurements or specialised 
equipment. The advantage of BMI is that it is easily calculated from two 
measurements, height and weight, standardly measured in many health settings. This 
study included a validation of BMI as a measure of pelvic adiposity.  
 
 
2.7 OBESITY AND PROSTATE MOTION 
 
At the time of protocol development, the effects of BMI on prostate motion over 
the course of EBRT treatment was not well documented, particularly intrafractional 
motion.  
 
The interfractional prostate displacement was investigated on pre-treatment CT 
on rail images in 329 patients (Wong et al., 2008). IGRT was performed on the first 5 
to 10 fractions only with a total of 1870 scans evaluated. BMI analysis was performed 
on 66 patients of the total cohort, however minimum, maximum and mean BMIs were 
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not reported, and there was no mention of how these 66 patients were selected, raising 
questions of potential bias. Interfractional prostate motion in overweight (BMI 25-30) 
and obese patients (BMI >30) compared to a control group of BMI <25 showed motion 
in the anterior/posterior direction to be significantly greater (p < 0.05) in the 
overweight group than the control and obese groups; and motion in the left/right 
direction significantly greater in the obese group (p <0.001) (Wong et al., 2008).  
 
The same group of authors further investigated the effect of BMI on prostate 
interfractional displacement. In addition to investigating the relationship with 
displacement and BMI, the patient’s weight and subcutaneous adipose tissue (SAT) 
was also measured and evaluated. Again, CT-on rails was the IGRT method of the first 
10-15 fractions only. There were strong correlations (p <0.01) between BMI, SAT and 
patient weight and LR prostate displacement, with 21.2% of the moderately to severely 
obese patients (BMI >35) demonstrating LR displacement of >1cm. The SI and AP 
directions were less correlated with BMI, SAT and patient weight (Wong et al., 2009).  
 
Rajendran et al., 2010 used electromagnetic tracking to determine that there was 
no association between interfractional prostate displacement and BMI in a cohort of 
28 patients. However, BMI descriptions were not given, and patients with more 
extreme BMIs may have been excluded due to the electromagnetic tracking limitation 
where the prostate must be within 23cm from the anterior body surface  (Rajendran et 
al., 2010).  
 
Intrafractional prostate motion assessed through pre- and post-treatment kV pair 
images was found to be significantly less (p=0.023) in the superior/inferior direction 
with patients with a higher BMI in a study by Thompson et al., 2011. No relationship 
was found between BMI and AP (p=0.056) or LR (p=0.37) displacements. A range of 
BMIs were assessed from 18 to 41.6 with a mean of 27.8 ± 4.2kg/m2. The authors 
hypothesised that increased adipose tissue in patients with higher BMIs may have a 
stabilising effect on SI intrafractional motion, however concluded that further 
investigation was warranted (Thompson et al., 2011). It is worth nothing that using the 
pre- and post- imaging method assumes that there was no further intrafractional motion 
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that would otherwise have been detected through real-time monitoring techniques, 
particularly when the treatment time parameters were not reported.  
In a study on 37 patients using real-time electromagnetic tracking, Shelton et al., 
2011 did not find any significant association with BMI and intrafractional motion, 
concluding that treatment time was the strongest predictor of motion. No BMI 
descriptions were given.  Similarly, Butler et al., (2012) did not find statistically 
significant difference in intrafractional standard deviation across BMI categories. 
Measuring intrafractional motion through electromagnetic tracking, the mean 
displacements in all 3 planes plus overall 3D vector were slightly less for higher BMIs, 
but not statistically significant (Butler, Morris, Merrick, Kurko, & Murray, 2012). The 
only BMI stratification however, was “Low BMI” (n =45) and “BMI ≥30” (n=21).  
 
2.8 SUMMARY 
The need for IGRT in the treatment of prostate cancer is well documented, and 
indeed recommended by the current Australian and New Zealand consensus guidelines 
(Hayden et al., 2010). While there are a number of IGRT solutions and commercial 
systems as summarised in Table 2.1, the ability to predict prostate motion promises to 
further improve the management of the prostate patients, improving accuracy of 
treatment delivery, which may improve treatment toxicities, thus improving quality of 
life of the prostate patient. As BMI is a simple measure of obesity, a correlation 
between BMI and prostate motion may allow for imaging protocols based on the 
patient’s BMI. Changes to the management of prostate patients undergoing radiation 
therapy based on BMI may include the possibility to evaluate imaging strategies and 
protocols, with the potential to reduce image workload in categories at low risk of 
motion, and increase image frequency, particularly intrafractional imaging in 
categories at high risk of motion.   
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Chapter 3: Research Design 
3.1 METHODOLOGY AND RESEARCH DESIGN 
A total of 130 patients of differing BMI were assessed for interfractional and 
intrafractional prostate displacement. Patients had three gold seed fiducial markers (a 
surrogate for the prostate position) inserted into the prostate which were clearly visible 
on imaging taken throughout the course of planning and treatment. The assessment of 
interfractional prostate displacement was performed by daily verification imaging with 
the patient in the treatment position to locate the fiducial markers, enabling the 
treatment staff to adjust patient positioning as necessary to accurately target the 
prostate. This imaging was as per the departmental prostate treatment protocol. The 
initial displacement, that is, the interfractional movement, was recorded for analysis. 
This is further detailed in 3.3.1. 
 
During the delivery of the daily treatment beams, movie loops of images were 
acquired using the iView electronic portal imaging device (EPID) (Elekta, Stockholm, 
Sweden). This allowed for assessment of daily intrafractional movement. Images were 
acquired approximately once every 5-10 seconds during treatment delivery, allowing 
for the evaluation and quantification of any prostate movement during this time, that 
is, intrafractional movement. This is further detailed in 3.3.2.  
 
Toxicities (particularly to the rectum, bladder and femoral head and necks) were 
graded using the Common Terminology Criteria for Adverse Events (CTCAE) 
Version 4 (National Cancer Institute, National Institute of Health: Publication No. 03-
5410) by the Radiation Oncologist on a weekly basis throughout treatment and at 3 
month, 6 month and 12 month follow-up. This is further detailed in 3.3.3. 
 
Additionally, patients completed a self-reported quality of life (QOL) 
questionnaire at the planning appointment (baseline); once a week throughout the 
duration of treatment, and at each follow up appointment at the completion of 
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treatment. The validated Quality of Life questionnaire (EORTC QLQ-C30) included a 
prostate cancer specific module (EORTC PR-25). This is further detailed in 3.3.4. 
 
Because BMI is not the only indication of obesity, the subcutaneous adipose 
tissue was measured from the treatment planning CT scan as an additional measure of 
obesity. This is further detailed in 3.3.5.  
 
3.1.1 Study Schema 
The overall study schema is detailed in Figure 3.1, including the data collection 
of inter- and intra-fractional motion, CTCAE toxicity gradings, and QOL responses. 
The treatment schema, detailing the collection of inter- and intrafractional motion data 
is summarised in Figure 3.2.  
 
 
Recruitment 
 
Allocation 
 
 
Assessment 
 
 
Follow Up 
 
 
Treatment 
Underweight 
<18.49 
 
Normal 
18.50 to 24.99 
 
Overweight 
25.00 to 29.99 
 
Obese 
>30.00 
 
Treated with daily interfractional 
prostate displacement correction 
 
Toxicity grading during 
treatment and at follow up 
 
Quality of Life assessed during 
treatment and at follow up 
 
Primary Endpoints: 
 BMI vs inter-fractional prostate displacement 
 BMI vs intra-fractional prostate displacement  
 
Secondary Endpoints: 
 BMI vs CTCAE toxicity gradings 
 BMI vs QOL 
 Prostate displacement over time 
 
Intrafractional prostate 
displacement assessed 
 
Patient consented prior to commencing 
radiation therapy treatment 
 
Patient’s BMI measured, and 
allocated to BMI group 
 
 
Figure 3.1. Overall Study Schema 
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Figure 3.2. Treatment Schema, including inter- and intra-fractional data collected 
 
 
3.2 PARTICIPANTS 
 
3.2.1 Eligibility 
Inclusion Criteria 
1. Patients with histologically confirmed malignant neoplasm of the prostate, 
suitable for gold seed fiducial marker implantation.  
Intra-fractional 
Inter-fractional 
Treatment 
Beams 
 
Direction 
Analysed 
 
Out of tolerance  
(>0mm for CBCT; 
≥3mm for stereoscopic 
pair) 
Within tolerance  
(0mm for CBCT; 3mm 
for stereoscopic pair) 
Pre-treatment verification 
CBCT/images taken 
 
Move as necessary & verify 
Commence Treatment  
Movie captures of each treatment 
beam acquired during treatment 
 
~7-8 frames 
~7-8 frames 
~3-4 frames 
LL / LPO 
Ant 
RL / RPO 
SI & AP 
SI & AP 
SI & LR 
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2. Performance status of equal to or less than 2 on the Eastern Cooperative 
Oncology Group (ECOG) scale. 
3. Patients must sign an informed consent prior to being placed in the study. 
 
Exclusion Criteria  
1. Evidence of distant or nodal metastases. 
2. Previous or concurrent cancers within the pelvis. 
3. Dose constraints to critical structures are not achieved  
4. Major intercurrent physical or psychiatric illness which would prevent 
completion of treatment or adequate follow-up either through disablement 
or limitation of life expectancy to less than 1 year. 
5. Performance status of greater than 2 on the ECOG scale. 
 
3.2.2 Sample Size calculation: 
To achieve statistically significant results, a sample size of 70 patients per BMI 
classification group was calculated, for a level of significance of 0.05 and power of 
80%. This was calculated to enable the detection of a displacement greater than 5 mm; 
which is clinically significant based on the standard prostate margins currently used 
for radiation therapy treatment.  
 
3.2.3 Consent Process: 
All participants provided written consent to participate in this study. All eligible 
participants were invited to participate at their fiducial implantation appointment.  The 
principal investigator or research assistant provided a verbal explanation of the study 
and the patient was given a patient information sheet, including a copy of the consent 
form and a copy of the QOL form. The patient was instructed to read the information 
sheet and encouraged to discuss their potential involvement with family, friends or 
other health professionals. The principal investigator or research assistant followed up 
with the patient on their planning appointment. If the patient had decided to participate, 
a consent form was signed and witnessed.  
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3.3 DATA COLLECTION AND COLLATION 
The fiducial markers implanted are clearly visible on imaging taken throughout 
the course of treatment and act as a surrogate for the prostate position, allowing for the 
measurement of interfractional and intrafractional prostate movement. 
 
3.3.1 Interfractional Motion 
Interfractional motion was measured on the daily pre-treatment CBCTs. 
Measurements were taken using the MOSAIQ record and verify system (Elekta, 
Stockholm, Sweden) to which each CBCT is automatically sent from the linac console. 
Where there was prostate rotation and deformation, fiducial markers were aligned to 
the best fit in six degrees of freedom. The displacement was recorded in millimetres 
for translational and degrees for rotational corrections. Where there was significant 
rotation (≥ 5 degrees), the investigator would verify the best fit match to the prostate 
contour from the planning scan; however this was at times impaired by the fiducial 
marker artefact, as demonstrated in Figure 2.3.  
 
For treatment correction, the FMs were aligned in a 3D translational best fit (that 
is, aligning in LR, SI and AP); however rotation (yaw, pitch and roll) was also 
examined in this study. Due to the potential variation between the 3D translational best 
fit match which was corrected prior to each treatment, and the 6 degrees best fit match, 
the difference was taken into account for the final analysis, with the 3D translational 
match subtracted from the 6 degrees of freedom match. 
 
The interfractional displacement was measured and recorded by the principal 
investigator and two research assistants. To assess the inter-user variability, the 
interfractional displacement, including translations and rotations of 10 patients were 
measured by all three users.  
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3.3.2 Intrafractional Motion 
Intrafractional motion was measured using movie loops captured during the 
anterior, left lateral and right lateral treatment fields. The movie captures were 
acquired and accessed using the iViewGT Version 3.4 acquisition software. Frames 
were captured at a rate of approximately 1 frame for every 2-5 seconds of treatment 
delivery. An average of 7-8 frames were acquired for the lateral fields, and 2-3 for the 
anterior field.  
 
Every second frame was evaluated and measured, meaning that an average of 4 
frames for each lateral aspect, and 1 frame for the anterior aspect was measured. For 
the laterals, the motion was assessed at approximately every 4-10 seconds.  The 
translational measurements were recorded in millimetres and rotational measurements 
in degrees. Left, superior and anterior displacements were defined as positive shifts, 
and right, inferior and posterior displacements were defined as negative shifts. Yaw 
was defined as positive for a clockwise rotation on the anterior aspect, that is, rotation 
of the prostate towards the right.  Pitch was defined as positive for the clockwise 
rotation on the left aspect, and anti-clockwise on the right aspect, that is, the rotation 
of the superior part of the prostate in a posterior direction.  
 
IView GT requires the outlining of the field edge on the Digital Reconstructed 
Radiograph (DRR) to determine the treatment isocentre, and relevant reference 
anatomy or surrogates such as the fiducial markers to determine the displacement. 
These outlines form a template, which can be overlaid on the captured image.  The 
field edge outline from the overlay is matched to the acquired movie capture frame 
and then to the relevant anatomy and/or surrogate, in this case the fiducial markers 
(Figure 3.3). The software gives the displacement relevant to the set field 
edge/isocentre position in millimetres and degrees.   
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Figure 3.3. Templates required on iView GT for matching, with field edge in red (a 
for LPO beam, c for Anterior beam) and centres of fiducial markers in green (b for 
LPO beam, d for Anterior beam). The field edge is matched (e), with the FMs 
matched for both translations and rotation (f).   
 
a 
c  d  
e f 
b
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As the fiducial markers can be difficult to identify on the DRRs in the lateral and 
oblique images, it was a requirement that the fiducial markers were outlined, and a 
marker placed in the centre of each fiducial marker to be visible prior to transferring 
the images from the planning system. This also ensured that another object such as a 
calcification which, if dense enough can appear similar to a fiducial marker, was not 
inadvertently selected on the DRR.  
 
When assessing each frame, if the fiducial markers could not be clearly identified 
due to artefact/s or poor image quality (Figure 3.4), the frame was marked in the 
database as “unidentifiable” with a code of 88888 for analysis purposes. When frames 
had been missed, either due to a single capture being accidently acquired by treatment 
staff rather than a movie loop, or the movie capturing of the particular beam or in some 
cases, fraction had been missed, this was also marked in the database as “missed” with 
a code of 99999 for analysis purposes.  
 
Figure 3.4. Example of a checkerboard artefact obscuring identification of markers 
on iView GT 
 
Where prostate rotation and/or deformation were visible, the best fit was 
measured (Figure 3.3e).  
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Where there was obvious large motion observed, the pelvic bony anatomy 
visible within the captures was assessed to ensure that the motion was an independent 
prostate motion and not a pelvic motion (e.g. the patient moving slightly, relaxing 
buttocks muscles etc.).  
 
As the intrafractional motion was measured by a single investigator for the 
majority of patients, inter-user variability could not be assessed on the whole study 
population (it was assessed for a subset of 8 images, over 20 users, as further detailed). 
However, the investigator was blinded to the patient’s BMI during the measurement 
process to prevent any systematics from biasing the result.   
 
A correction for gantry sag at the lateral and posterior oblique movie capture 
angles was applied. Each of the three linacs in the department had a different measured 
sag, ranging from a minimum of 0.75 mm to maximum of 1.25 mm. As most patients 
were treated on a single linac, with only very few treatments on other linacs, the gantry 
sag relative to the linac the patient was treated on for the majority of the fractions was 
applied. The gantry sag correction was applied through the automatic calculation 
function in SPSS.  
 
Inter-user and Intra-user Variability 
Investigation into the inter-user and intra-user variability when measuring the 
prostate displacement was performed. Inter-user variability can be defined as the 
variability that may arise between different users performing a match on the same 
image. Intra-user variability can be defined as the variability that may arise when the 
one operator performs repeated measurements, and was performed as discussed above.  
 
Fiducial markers are still subject to this inter- and intra-user variability, 
particularly as the length of the marker (3mm) can cause some ambiguity. The 
variablity is compounded when there is prostate deformation and/or rotation visible, 
as the operator is required to obtain the “best fit” which can be subject to interpretation.  
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To investigate inter-user variability of the movie capture matches, 20 radiation 
therapists with a range of experience were asked to assess and measure the prostate 
displacement on a total of eight images (1 Right aspect, 4 Left aspect, 3 Anterior 
aspect) from four study participants. Additionally, they were instructed to perform 
each measurement a total of three times to evaluate intra-user variability. The principal 
investigator also performed three matches on these eight images to evaluate and 
compare the intra-user variability.  
 
3.3.3 Toxicity 
Toxicity was graded by the Radiation Oncologist or Registrar during the 
patient’s weekly treatment review appointment using the internationally validated 
Common Terminology Criteria for Adverse Events (CTCAE V4.0) at baseline, during 
treatment and at follow up appointments. The gradings were recorded in the MOSAIQ 
patient information system (Elekta, Stockholm, Sweden), and were aggregated by the 
principle investigator. The CTCAE V4.0 is the standard toxicity grading used for all 
radiation oncology patients within the department, and therefore for consistency this 
was maintained for this study.  
 
The particular toxicities graded were: 
 Fatigue 
 Weight Gain 
 Weight Loss 
 Bloating 
 Constipation 
 Diarrhoea 
 Faecal Incontinence 
 Flatulence 
 Haemorrhoids 
 Nausea 
 Vomiting 
 Dehydration 
 Urinary Frequency 
 Urinary Incontinence 
 Urinary retention 
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These were selected as the most commonly experienced during EBRT, and closely 
matched the QOL questions asked.  
 
3.3.4 Quality of Life 
Patient-reported quality of life was measured using the internationally validated 
European Organisation for Research and Treatment of Cancer QLQ questionnaire 
(EORTC QLQ-C30 V3.0) with a prostate cancer specific module (EORTC PR-25).  
 
The questionnaire was self-administered at the patient’s planning appointment 
(baseline); during treatment at week 2, 4, 6 and 8; and at follow up at 3 months, 6 
months and 12 months after treatment. During treatment, the patient was handed the 
questionnaire at their treatment appointment and instructed to return the completed 
form at the following treatment appointment. Follow up questionnaires were posted to 
the participant with a postage-paid self-addressed envelope to return the form to the 
investigators.  
 
If the participant did not have adequate literacy to complete the QOL forms and 
there were no available friends or family to assist, a staff member not involved in the 
project read the QOL questions to the patient and transcribed their answers. The QOL 
forms were available in multiple languages, as translated by the EORTC, however no 
patients required this.   
 
The EORTC form was chosen for its simple yet comprehensive nature, covering 
the key domains of urinary function, bowel function and sexual function, in addition 
to social and emotional quality of life issues. Published data from the use of this form 
are available enabling a comparison with the data collected in this study.  
 
3.3.5 BMI & Pelvic Adiposity 
BMI is a simple measure of weight relative to height squared (kg/m2). Height 
was measured to the nearest 0.5cm using a standard wall-mounted stadiometer. Weight 
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was measured on the same departmental scales to the nearest 0.1kg. All patients were 
weighed in their clothing, removing any heavy clothing and shoes. Height and weight 
were used to calculate each patient’s BMI. Both height and weight measurements were 
taken on the patient’s planning day, with weight repeated throughout treatment 
(weekly or fortnightly).  Any changes in patient’s BMI over the course of treatment 
were taken into account for the final analysis.  
 
To verify that BMI was an appropriate surrogate for the pelvic adiposity of the 
cohort, pelvic adiposity was measured on the CT scans of 75 of the study patients.  
Pelvic subcutaneous adipose tissue (SAT) was measured on the CT scans using three 
methods. Method one and two measured the SAT at the same radiation therapy 
treatment set up point. In method one, SAT was measured in the anterior, posterior 
and lateral directions at the mid-point of the transverse CT slice. This is demonstrated 
in Figure 3.5 and these four measurements were summed to produce a single metric. 
In method two, the SAT was manually outlined by the one investigator on the one 
transverse slice of each CT scan using the radiation therapy planning program Focal 
Version 4.70 (Elekta CMS, Missouri, USA). The software was able to calculate the 
outlined SAT volume, as shown in Figure 3.6.  
 
Figure 3.5. SAT measured in anterior, posterior and lateral directions 
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Figure 3.6. SAT manually outlined on transverse CT slice 
 
The third method was performed on 25 randomly selected CT scans from the 75-
patient cohort. The SAT was outlined by the same investigator for each transverse CT 
slice, 2 cm superior and 2 cm inferior to the treatment set up point, and the SAT volume 
was then calculated. Figure 3.7 illustrates and example of the outlined region.  
 
Figure 3.7. SAT manually outlined over volume 
Ant 
Right 
Sup 
Right 
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3.4 TREATMENT DETAILS 
3.4.1 Fiducial Marker Implantation:  
As part of standard treatment, study participants had three gold seed fiducial 
markers inserted into the prostate. These were inserted by one of two trained Radiation 
Oncologists.  
 
Patients undertook suppository preparation (Microlax enema, Pharmacia 
Australia) the night before and morning of the procedure, and commenced a course of 
prophylactic antibiotics (Norfloxacin, Merck & Company, Inc., US) one day prior to the 
procedure.  
 
The insertion procedure was performed under ultrasound guidance with the use 
of a transrectal ultrasound transducer. The patient was stabilised in the left lateral 
decubitus position.  A local anaesthetic (5 ml 2% lignocaine) was given at the 
periprostatic neurovascular bundle to act as a nerve block. Each fiducial marker was 
inserted via a 17-gauge needle (CIVCO Medical Solutions, Iowa, USA), positioned 
using the ultrasound images.  
 
Optimal positioning of the markers was right base, right apex and left mid-zone 
of the prostate.  This was dependent upon the size and visibility of the prostate, with a 
smaller prostate volume impeding optimal placement.  
 
Implantation occurred at least one week prior to the patient’s planning CT scan 
appointment to allow for any oedema from the implant procedure to subside.  
 
3.4.2 Simulation Details: 
Participants were simulated according to current departmental protocol. Patients 
were positioned supine on the solid carbon-fibre CT couch top, with a standard head 
rest, arms on chest, kneefix under knees and footstocks supporting feet and ankles.  
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Planning CT scans (120 kV, 130mAs, slice thickness of 2mm to ensure all 3 
fiducials markers were included on slices) of the pelvis were acquired using a Siemens 
Somatom Sensation CT scanner (Siemens Healthcare, Erlangen Germany).  
 
Prior to the scan, patients undertook preparation to ensure an empty rectum and 
full bladder. The rectum was measured to ensure it was less than 4.5cm in diameter at 
the level of the prostate. The Radiation Oncologist was consulted if this was not 
achieved, and the patient was asked to evacuate his bowels; if necessary an enema was 
administered prior to the patient being rescanned. Likewise, if the bladder volume was 
deemed unacceptable (either too empty or too full), the patient was taken off the CT 
couch and instructed to either empty his bladder and re-drink, or to drink some more 
water.  
 
 
3.4.3 Bowel and Bladder Preparation Protocol: 
 
The standard bowel and bladder preparation protocol for prostate cancer patients 
treated within our department is to have an empty rectum/bowel and full bladder. This 
is achieved by the patient: 
 Taking a sachet of Movicol laxative every morning following breakfast, 
one week prior to and including simulation day, and then everyday 
throughout the course of treatment.  
 Emptying their bladder then drinking 300ml of water 20 minutes prior to 
their simulation scan, and then everyday through the course of treatment.  
At the time of receiving their simulation appointment letter, patients are given 
instructions on taking Movicol. They are then educated at presentation to the 
department on instructions for a full bladder, and the importance of the bowel and 
bladder preparation compliance.  
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3.4.4 Planning Details:  
The assigned planning radiation therapist contoured structures including patient, 
bladder, rectum, and femoral heads and necks on the FOCAL system (Elekta CMS, 
Missouri, USA). The fiducial markers were also contoured at appropriate window 
levelling to reflect their true size. The consultant radiation oncologist contoured the 
prostate, seminal vesicles (SVs) and PTVs, and verified the critical structures contours.  
 
The Radiation Oncologist prescribed one of the following: 
 
 Phase 1 (PTV = expansion on prostate +/- SVs, depending upon staging): 
78Gy/39# 
Or 
 Phase 1 (PTV = expansion on prostate + SVs): 60Gy/30#; Phase 2 (PTV 
= expansion on prostate only): 18Gy/9# 
 
 
As per department protocol, the PTV expansion was 1cm uniformly except in 
posterior aspect where a 5-7 mm expansion was applied.  
 
Patients were planned on the XiO planning system (Elekta CMS, Missouri, USA) 
according to departmental protocols. A 3D conformal “sunrise” technique was used, 
with laterals, anterior obliques and a direct anterior beam (Figure 2.2). Lateral beams 
may have been angled slightly posteriorly to achieve dosimetric constraints.  
 
If issues arose in achieving constraints (Table 3.1), particularly to the rectum, 
the prescribing Radiation Oncologist was consulted. Consultation with the Radiation 
Oncologist usually resulted in reduction of the total prescription dose, or reduction in 
Phase 1 dose while maintaining the total prescription dose of 78Gy to the prostate.   
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Table 3.1 
Dose Constraints to Critical Structures  
Rectum 75Gy <15% of volume 
70Gy <30% of volume 
65Gy <40% of volume 
Femoral Head & Necks 35Gy <100% of volume 
45Gy <60% of volume 
60Gy <30% of volume 
 
 
3.4.5 Treatment Details:  
Patients were treated on the department’s megavoltage (10 MV) linear 
accelerators. Patients were queried each day as to their adherence to the bladder and 
bowel protocol. If the patient reported troubles, particularly in emptying their bowel 
that day, alterations to the aperient schedule were considered.   
 
Patients were treated daily on weekdays. Treatment times varied throughout the 
course of treatment, between the hours of 8am and 8pm. In the event of a public 
holiday or other event resulting in no treatment on a scheduled day (such as linac 
issues) within the treatment course, the patient was scheduled for a bi-daily fraction at 
the discretion of the treating Radiation Oncologist. A maximum of 3 bi-daily 
treatments were allowed as per department protocol.  
 
 
3.4.6 IGRT Details 
 
The Elekta Synergy and Axesse linear accelerators have the following imaging 
capabilities:  
 XVI – kilovoltage (kV) imaging 
 iViewGT - megavoltage (MV) imaging 
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As per current departmental protocol (Appendix 6.1), a pre-treatment CBCT was 
acquired and the fiducial markers matched with the simulation CT, using XVI Synergy 
4.2.1 or AxesseTM (Elekta, Stockholm, Sweden). The CBCT scan was acquired 
utilising our department’s FM scan protocol, which is a 200 degree CBCT, allowing 
enough information to be assessed while minimising dose to the patient. Further details 
of the CBCT scan can be found in Table 3.2.  
 
Table 3.2 
CBCT Settings 
Parameter: Setting: 
Collimation S10 
Filter F0  
Frames 361 
Start angle 250 
Stop angle 90 
kV 120 
mAs 577.6 
Scan dose 28.5mGy 
 
Based upon the CBCT match, the patient set-up was corrected by shifting the 
couch using the Remote Automatic Table Movement function, that is, the movement 
of the couch was performed from the outside treatment console. The action level was 
0mm. This removes the risk of human error in moving the couch. The auto-couch 
function is checked each day during the linear accelerator’s warm up and quality 
assurance procedure. This auto-couch function will only perform movements of <2cm. 
If a greater move is required, the treatment staff must enter the room to perform the 
movement.  
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During the correction movement of the couch, the patient was monitored by the 
treatment radiation therapists to ensure they did not move significantly. The patient 
was informed that the couch will move, however it cannot be guaranteed that the 
patient did not involuntarily move slightly at the couch movement, particularly in the 
first few fractions as they adjusted to the routine.  
  
As the treatment couch can only correct for the 3 translational errors 
(anterior/posterior, superior/inferior, and left/right), and not rotational errors (yaw, 
pitch, roll) when correcting for interfractional motion online, only the “best-fit” in the 
translational error was corrected. Treatment staff utilise the automatic registration 
algorithm with the clipbox set around the seeds. Any rotation was removed, and a 
manual adjustment to best fit performed as necessary, verified by the second treatment 
RT before “convert to correction” was applied. Figure 3.8 b and c shows an example 
of a “best-fit” match. The shifts made on the day of treatment were recorded in 
millimetres.  
 
If the CBCT functionality was not operational on a certain fraction, the patient’s 
setup was verified and corrected utilising kV or MV matches, requiring a manual 
adjustment of the couch. When this was the case, a tolerance of 3 mm was applied. 
These fractions were excluded from the analysis. The occurrence of this is detailed in 
Section 4.2.  
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Figure 3.8. An example of the daily variation of the same patient (i=coronal, 
ii=sagittal, iii=transverse), with (a) representing a fraction with little variation, and a 
good match to FMs (red, green and blue outlines), (b) representing a fraction with 
some variation, particularly in bladder volume (yellow) and to a lesser extent, rectal 
volume (purple) with a best fit match performed to FMs, and (c) representing a 
fraction with significant difference in rectal volume due to gas, with a best fit match 
performed to FMs 
 
3.5 PROCEDURE AND TIMELINE 
3.5.1 Recruitment Feasibility 
The Townsville Cancer Centre curatively treats an average of 150 to 200 patients 
per year with a primary diagnosis of prostate cancer. Making allowances for those 
patients who may not be suitable for fiducial marker implantation, may not meet 
eligibility criteria, and a small number of patients who may not complete a course of 
treatment, it was anticipated that a minimum of 150 patients per year would be suitable 
to approach for this study.  
 
a-i a-ii a-iii 
b-i 
c-i 
b-ii 
c-ii 
b-iii 
c-iii 
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An audit of 431 prostate patients treated with radiation therapy between 2007 
and 2009 at the Townsville Cancer Centre revealed the following proportions of BMI 
classification, in agreement within 5% of the National Health Survey Results:  
 
Table 3.3 
National Health Survey BMI Proportions 
BMI Classification Number Percentage 
Underweight 3 0.7% 
Normal 95 22.0% 
Overweight 189 43.9% 
Obese 144 33.4% 
TOTAL 431 100% 
 
While an underweight classification group would be ideal, realistically it was 
expected that statistically significant numbers for this group would not be reached. 
Underweight patients were approached to participate and the data analysed even 
though this would not be statistically significant. It was expected that while not 
statistically significant, the data gained from any underweight patients will be of 
clinical interest, and could be combined with the normal BMI category for final 
analysis. It was planned to recruit all eligible patients within a 2.5 year time frame. 
Recruitment of 130 patients occurred from June 2011 to April 2013 (22 months).  
 
3.6 ANALYSIS 
The aims are summarised in Table 3.4.  
 
All data (as summarised in Table 3.5 and Table 3.6) was collected and analysed 
in SPSS Version 19.0 software (IBM, Armonk, NY). Where there was missing data 
for any of the components (CBCT, Movie captures, CTCAE toxicity gradings and 
QOL form responses), the partial data was utilised for analysis. Analysis was achieved 
through syntax in SPSS.  
 
An interim analysis was performed on the first 50 patients, performing linear 
regression analysis on both inter and intra-fractional prostate displacement vs BMI.  
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Table 3.4 Overview of Aims and Statistical Test performed 
To analyse: Test performed: Description: 
Prostate Displacement vs. BMI Linear Regression Analysis 
 
Analysis of Variance 
(ANOVA) 
The mean interfractional and 
intrafractional displacements of 
the 4 BMI patient groups were 
assessed for statistically 
significant difference 
Prostate Displacement vs. 
Toxicity 
ANOVA The mean interfractional and 
intrafractional displacements and 
the toxicity gradings were 
assessed for statistically 
significant difference 
Prostate Displacement vs. QOL ANOVA The mean interfractional and 
intrafractional displacements and 
QOL domains were assessed for 
statistically significant difference 
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Table 3.5 Data measured and calculated for Obesity, Interfractional and Intrafractional Prostate 
Motion 
 Measured Data 
Repeat 
Frequency 
Calculated Data 
Per Patient 
Calculated 
Data Per 
BMI 
Group 
Calculated 
Data Per 
Population 
Statistical 
Analysis 
O
b
e
si
ty
 
Height Planning 
BMI 
Mean and 
SD 
Mean and 
SD 
Linear 
Regression 
Analysis 
Weight 
Planning; once 
per fortnight 
during treatment 
Adiposity Planning scan 
Pelvic adiposity (cc) 
for 75 patients only 
In
te
r
#
 P
ro
st
a
te
 M
o
ti
o
n
 
Left/Right 
All fractions 
Vector per fraction 
 
Displacement 
(translation, rotation 
& vector) over 
course of treatment: 
Min, Max, 
Difference, Mean, 
Median, Standard 
Deviation 
Mean and 
SD 
Mean and 
SD 
Linear 
Regression 
Analysis 
 
ANOVA 
Anterior/Posterior 
Superior/Inferior 
Pitch 
Yaw 
Roll 
In
tr
a
#
 P
r
o
st
a
te
 M
o
ti
o
n
 
L
ef
t 
 
Sup/Inf 
3 to 11 frames 
per fraction, 
every second 
frame measured 
Displacement over 
each fraction: : Min, 
Max, Difference, 
Mean, Median, 
Standard Deviation 
 
Displacement over 
course of treatment: 
: Min, Max, 
Difference, Mean, 
Median, Standard 
Deviation 
Mean and 
SD over 
course of 
treatment 
Mean and 
SD over 
course of 
treatment 
Linear 
Regression 
Analysis 
 
ANOVA 
 
Range and 
Frequency 
Assessment 
Ant/Post 
Pitch 
A
n
te
ri
o
r 
 Sup/Inf 1 to 5 frames per 
fraction, every 
second frame 
measured 
Left/Right 
Yaw 
R
ig
h
t 
 
Sup/Inf 3 to 11 frames 
per fraction, 
every second 
frame measured 
Ant/Post 
Pitch 
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Table 3.6 Data measured and calculated for Toxicity and Quality of Life 
 Measured Data 
Repeat 
Frequency 
Calculated Data 
Per Patient 
Calculated 
Data Per 
BMI 
Group 
Calculated 
Data Per 
Population 
Statistical 
Analysis 
T
o
x
ic
it
y
: 
C
T
C
A
E
 G
ra
d
in
g
 
Fatigue 
Baseline 
 
Treatment: 
Week 2 
Week 4 
Week 6 
Week 8 
 
Follow Up: 
3 Months 
6 Months 
12 Months 
Min, Max, Mean, 
Standard Deviation 
Mean and 
SD for each 
time point 
Mean and 
SD for each 
time point 
ANOVA 
Weight Gain 
Weight Loss 
Bloating 
Constipation 
Diarrhoea 
Faecal Incontinence 
Flatulence 
Haemorrhoids 
Nausea 
Vomiting 
Dehydration 
Urinary Frequency 
Urinary Incontinence 
Urinary retention 
Q
O
L
: 
E
O
R
T
C
 f
o
rm
 
F
u
n
ct
io
n
al
 Q
L
Q
-C
3
0
 
Global Health 
Status 
Baseline 
 
Treatment: 
Week 2 
Week 4 
Week 6 
Week 8 
 
Follow Up: 
3 Months 
6 Months 
12 Months 
Raw Score & 
Linear 
Transformation 
Score for each scale 
Mean and 
SD for each 
time point 
Mean and 
SD for each 
time point 
ANOVA 
Physical 
Functioning 
Role Functioning 
Emotional 
Functioning 
Cognitive 
Functioning 
Social 
Functioning 
S
y
m
p
to
m
 Q
L
Q
-C
3
0
 
Fatigue 
Nausea & 
Vomiting 
Pain 
Dyspnoea 
Insomnia 
Appetite Loss 
Constipation 
Diarrhoea 
Financial 
Difficulties 
F
u
n
ct
io
n
al
 Q
L
Q
-P
R
2
5
 
S
y
m
p
to
m
 Q
L
Q
-P
R
2
5
 
Sexual Activity 
Sexual 
Functioning 
Urinary 
Symptoms 
Bowel 
Symptoms 
Hormonal 
treatment- 
related 
symptoms 
Incontinence aid 
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3.6.1 Obesity  
BMI 
BMI was calculated using the World Health Organisation (WHO) definition of 
the weight (kilograms) divided by the square of the height (metres) (World Health 
Organisation, 2013). These were then categorised in the database according to the 4 
major WHO classifications (Underweight, Normal, Overweight and Obese), as per 
Table 3.7. This was performed using the calculation feature in SPSS, with the BMI 
classification as a categorical variable.   
 
Table 3.7 World Health Organisation Classifications of BMI 
Classification BMI (kg/m2) 
Underweight <18.50 
Severe thinness <16.00 
Moderate thinness 16.00 - 16.99 
Mild thinness 17.00 - 18.49 
Normal range 18.50 - 24.99 
Overweight ≥25.00 
Pre-obese 25.00 - 29.99 
Obese ≥30.00 
Obese class I 30.00 - 34-99 
Obese class II 35.00 - 39.99 
Obese class III ≥40.00 
 
Pelvic Adiposity 
A linear regression analysis was performed on Adipose Total vs. BMI (Method 
One) and Adipose Volume vs. BMI (Method Two and Method Three), using the three 
methods defined in Section 3.3.5.  
 
3.6.2 Interfractional Prostate Motion 
The displacement of the prostate was measured and recorded in all 6 degrees of 
freedom (translation: left/right, anterior/posterior, superior/inferior; rotational: pitch, 
yaw, roll).  From this, the following was calculated (as summarised in  
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Table 3.5): 
 
Per fraction 
The displacement vector for each fraction was calculated. This vector takes the 
three translational measurements to produce a single quantity, or magnitude. 
 
This was calculated by:  
𝑉𝑒𝑐𝑡𝑜𝑟 =  √𝑆𝐼2 + 𝐿𝑅2  + 𝐴𝑃2  
 
 
Per patient 
For each patient, the descriptive statistics (including minimum, maximum, 
range, mean and standard deviation) of each translation, rotation and the vector was 
calculated over the course of the treatment.  
 
Per BMI group 
For each BMI group, the mean and standard deviation of each translation, 
rotation and the vector was calculated over the course of the treatment.  
 
 
Per Population 
For the overall sample, the mean and standard deviation of each translation, 
rotation and the vector was calculated over the course of the treatment.  
 
 
Analysis 
A linear regression analysis was performed on the patient’s total treatment 
interfractional mean (that is, the mean over the 37 to 39 fractions) for each translation, 
rotation and vector.. 
 
 54 Research Design 
 
3.6.3 Intrafractional Prostate Motion 
The displacement of the prostate was measured and recorded on every second 
frame for each captured treatment field, including the relevant translational and 
rotational measurements (Left & Right aspects: Superior/Inferior, Anterior/Posterior, 
Pitch; Anterior aspect: Superior/Inferior, Left/Right, and Yaw). Gantry sag correction 
was applied to the left and right aspects, as detailed in Section 3.3.2. From this, the 
following was calculated (as summarised in  
Table 3.5): 
 
Per fraction 
The displacement over each fraction for each measured translation and rotation 
including minimum, maximum, range, mean and standard deviation was calculated.  
 
 
Per patient 
For each patient, the descriptive statistics (including minimum, maximum, 
range, mean and standard deviation) of each translation and rotation was calculated 
over the course of the treatment.  
 
Per BMI group 
For each BMI group, the mean and standard deviation of each translation and 
rotation was calculated over the course of the treatment.  
 
 
Per Population 
For the overall sample, the mean and standard deviation of each translation and 
rotation was calculated over the course of the treatment.  
 
Analysis 
A linear regression analysis was performed on BMI vs the patient’s total 
treatment intrafractional mean (that is, the mean over the 37 to 39 fractions) for each 
translation and rotation. 
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3.6.4 Toxicity 
Basic descriptive statistics were calculated for each patient, including the 
minimum, maximum, mean and standard deviation for each toxicity grading.  
 
3.6.5 Quality of Life  
As per the EORTC scoring manual (Fayers et al., 2001), the raw data from the 
QOL form responses were calculated to produce the: 
 Raw score – the average of each item contributing to the particular scale 
 Linear Transformation – the standardisation of the raw score to a scale of 0 
to 100, with the higher score for functional scales representing a higher level 
of functioning, and a higher score for symptom scales representing a higher 
level of symptoms.  
This was calculated using SPSS. 
 
3.6.6 Inter- and Intra-user variability 
The inter- and intra-user variability analyses on both the interfractional and 
intrafractional data are summarised below in Figure 3.9.  
 
 
 
 
 
 
 
 
 
Intrafractional Data 
Inter-user  
Variability 
Intra-user  
Variability 
8 movie capture images of 4 patients 
matched 3 times each by 20 different 
users, and the principal investigator 
Differences 
between 20 
users’ 
matches 
assessed 
Differences 
between 3 
repeated 
matches 
assessed 
Interfractional Data 
Inter-user  
Variability 
All CBCTs of 10 patients measured by 2 
research assistants and principal 
investigator 
Differences 
between 3 
users’ 
matches 
assessed 
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Figure 3.9. Inter- and Intra-user Variability Analyses 
 
Interfractional Measurements 
Three different users of varying levels of clinical experience (2-8 years) 
measured the interfractional displacements on the CBCTs; the principal investigator 
and two research assistants all performed measurements on the same 10 patients. 
Analysis was then performed on these patients to ensure that the interuser variability 
was acceptable to justify the remaining 120 patients being analysed by different users.  
 
Intrafractional Measurements 
Inter-user variability 
The principal investigator alone measured the intrafractional motion on the 
movie captures. This was intentional to eliminate inter-user variability. An abbreviated 
analysis on inter-user variability was performed, with 20 radiation therapist staff of 
varying levels of clinical experience (1-12years) measuring the intrafraction motion 
on eight sets of images of four different patients (2 images per patient). Each image 
set was matched three times by each staff member.  
 
Intra-user variability 
The intra-user variability of the principle investigator was assessed through the 
repeated measures of images of the same patients as above. This was analysed using 
descriptive statistics.  The standard deviation from the staff group (inter-user & intra-
user) and the principal investigator (intra-user) was analysed.    
 
3.7 ETHICS AND LIMITATIONS 
3.7.1 Ethical Considerations 
The study was reviewed and approved by the Townsville Hospital and Health 
Service Human Research and Ethics Committee in December 2010. An extension was 
applied for and received in December 2012 (Appendix 6.1).  
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No additional radiation dose was given as a part of this study, as the movie 
captures were captured during treatment delivery itself, and there was no deviation 
from standard treatment and verification protocols.  
 
The main ethical consideration was the inconvenience and time required for the 
participants to complete the QOL forms at the various intervals. This was alleviated 
through allowing the participants to take the forms home overnight during treatment, 
and supplying a self-addressed, postage paid return envelope for the follow up forms.  
 
3.7.2 Limitations 
A major limitation of the movie capture methodology is the lack of real-time 3D 
data – that is, only one aspect with its relevant displacements (SI, AP, and LR) can be 
collected and measured at any given time. This is discussed further in Section 5.5.3.  
 
Another limitation was the lack of data on prostate deformation. At present, there 
is no efficient way to gather measurements on prostate deformation in either XVI, 
MOSAIQ or IView, and therefore this was beyond the scope of this project. The 
presence of prostate motion requires a “best-fit” match which introduces subjectivity.  
The ramifications of this are further discussed in Section 5.3.  
 
As already discussed in Section 3.5.1, it was not expected to accrue a statistically 
significant underweight sample, a limitation which could only realistically be achieved 
through a large, multi-site accrual process.  
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Chapter 4: Results 
4.1.1 Screening & Recruitment 
Of a total of 177 patients screened, 156 were eligible over a time period of 22 
months (July 2011 to April 2013) with ineligibility factor details summarised in Table 
4.1 Of those eligible, 24 declined participation, yielding a consent rate of 84.6%. The 
most common reason given for patient non-participation was the patient did not wish 
to complete the QOL forms.  
 
During interim analysis of the first 50 patients, where a clear null result was 
evident, it was decided by the investigating team to close recruitment. 132 patients had 
been recruited, with 1 patient deceased due to another medical condition prior to the 
commencement of treatment, and one patient refusing to commence treatment. This 
resulted in a total sample size of 130 participants, and as a result, the statistical power 
of the study was reduced to 0.72. The rate of accrual versus the rate of anticipated 
accrual is shown in Figure 4.1.  
Figure 4.1 Anticipated accrual versus actual accrual 
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Table 4.1 
Rates of ineligibility during screening 
Ineligibility factor Rate (%) 
ECOG ≥2 1 (5%) 
Hip Prosthesis 7 (33%) 
Previous or concurrent pelvic cancer 4 (19%) 
Cognitive 4 (19%) 
Procedural difficulties resulting in suboptimal insertion of FMs 2 (10%) 
Treatment variations (IMRT, prostate + nodes, high dose palliative) 3 (14%) 
TOTAL 21 (100%) 
 
4.2 PATIENT SPECIFICS & DATA COLLECTION RATES 
The median age was 71 years (Range: 51 to 86). The majority of patients (85.4%) 
were on hormonal therapy. In most patients (82.3%), the SVs were within the treatment 
volume for at least the first phase of treatment. Diagnosis, PSA and staging are detailed 
in Table 4.2. All patients were free of metastases at the time of treatment, and did not 
have localised nodal disease. Sixteen patients (12.3%) had fewer than three FMs at the 
time of treatment, due to loss of a FM between implantation and simulation.  
 
The mean BMI was 29.4 kg/m2 across the study cohort (range of 18.22 to 47.00 
kg/m2).  A minority of the cohort was within the normal BMI range (18.5%), with 
only 1 patient in the underweight category (Figure 4.2). There was a relatively even 
distribution of the remainder of patients between the overweight and obese BMI 
categories (Table 4.3). For analysis, the underweight and normal BMI categories were 
combined unless otherwise specified.  
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Table 4.2 
Patient Characteristics 
Parameter Group Number Percentage 
Dose (Gy) 78 109 83.8% 
76 10 7.7% 
74 11 8.5% 
Clinical T Stage T1a 5 3.8% 
T1b 7 5.4% 
T1c 31 23.8% 
T2a 13 10.0% 
T2b 12 9.2% 
T2c 41 31.5% 
T3a 17 13.1% 
T3b 3 2.3% 
T3c 1 0.8% 
T4 5 3.8% 
Gleason score 5 2 1.5% 
6 29 22.3% 
7 50 38.5% 
8 14 10.8% 
9 33 25.4% 
10 1 0.8% 
Unknown 1 0.8% 
PSA at Diagnosis ≤10 68 52.3% 
10-20 41 31.5% 
≥20 21 16.2% 
Hormone Therapy Yes 111 85.4% 
No 19 14.6% 
Seminal Vesicles Inclusion Entire course 34 26% 
Partial course 73 56% 
Not included 23 18% 
Fiducial Markers 3 markers 114 87.7% 
2 markers 14 10.8% 
1 marker 2 1.5% 
Previous TURP History Yes 18 13.8% 
No 112 86.2% 
  
Table 4.3 
BMI distribution 
 
 
 
BMI Classification Number Percentage 
Underweight 1 0.8% 
Normal 24 18.5% 
Overweight 56 43.1% 
Obese 49 37.7% 
TOTAL 130 100% 
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Figure 4.2. Histogram of BMIs of recruited patients 
 
CBCT Data  
A pre-treatment CBCT was acquired for each of the 5038 fractions except for a 
total of seven fractions in five patients, where CBCT was not operational (median total 
CBCT per patient: 39, Range: 37-39). These fractions were excluded for movie capture 
data, as image guidance for these few fractions was portal images with a 3 mm action 
threshold.  
 
On the 11 occasions where a patient had two CBCTs for one fraction (for reasons 
such as needing to expel gas etc.), only the CBCT that was used for set up verification 
and treatment was analysed.  
 
Of the 5031 total CBCTs acquired, 48 could not be retrospectively evaluated due to a 
software error in opening up the CBCT data in the record and verify system. While the 
record and verify system records the shifts made on a daily basis, this information does 
not include the rotational displacements, and therefore these 48 CBCTs were excluded 
from analysis.  Thus, a total of 4983 CBCTs were analysed.  
 62 Results 
 
 
Movie Capture Data  
Across all patients, a total of 4357 out of 5038 fractions (86.5%) had complete 
or partial movie capture data collected.   
 
Toxicity Data  
CTCAE data recorded was poor, with only 82 patients (63%) having some or all 
scores recorded throughout treatment. No follow up CTCAE data was recorded.  
In the 82 patients who did have some or all data recorded, there were a possible 
328 treatment occasions to record CTCAE data (in weeks 2, 4, 6 and 8 of treatment). 
Of these, 151 occasions had complete data recorded (46%) and 73 had partial data 
recorded (22%). A further breakdown of the data collected is presented in Table 4.4. 
Table 4.4 CTCAE data recorded per time point and BMI category 
Time Point Complete data Partial data 
2 weeks TOTAL:36 
U’Weight/Normal:5 
Overweight:17 
Obese:14 
TOTAL:13 
U’Weight/Normal:5 
Overweight: 2 
Obese: 6 
4 weeks TOTAL: 41 
U’Weight/Normal: 7 
Overweight: 14 
Obese: 20 
TOTAL:15 
U’Weight/Normal: 3 
Overweight: 7 
Obese: 5 
6 weeks TOTAL: 36 
U’Weight/Normal: 7 
Overweight: 14 
Obese: 15 
TOTAL: 21 
U’Weight/Normal: 2 
Overweight: 10 
Obese: 9 
8 weeks TOTAL: 38 
U’Weight/Normal: 6 
Overweight: 20 
Obese: 12 
TOTAL: 24 
U’Weight/Normal: 5 
Overweight: 11 
Obese: 8 
 
 
QOL forms 
Of the 1040 QOL forms handed out, a total of 856 were returned completed or 
partially completed (Table 4.5).  
Table 4.5 
Return rate of QOL forms 
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QOL form Missing forms Return Rate (%) 
Baseline 37 71.5% 
2 weeks 14 89.2% 
4 weeks 9 93.1% 
6 weeks 13 90.0% 
8 weeks 23 82.3% 
3 month follow up 24 81.5% 
6 month follow up 32 75.4% 
12 month follow up 32 75.4% 
TOTAL 184 82.3% 
 
Follow Up Rates 
Eight patients were lost to follow up for QOL due to various reasons as detailed 
in Table 4.6.  
Table 4.6 
Rate of loss to follow up 
Loss to Follow Up Rate (%): 
No current address 1 during follow up 
Other medical condition 2 during treatment – placement of indwelling catheters 
1 during follow up – onset of dementia 
Other malignancy 2 during follow up – one breast; one melanoma 
Death 1 prior to commencement of treatment 
1 during follow up 
 
4.3 BMI & PELVIC ADIPOSITY 
The relationship between BMI and pelvic adiposity was investigated, with 
analysis performed on the data collected as outlined in Section 3.3.5.  
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A linear regression analysis revealed a strong relationship between BMI and 
pelvic adiposity. R2-values for measurement of adipose tissue using method one and 
two were 0.841 and 0.866 respectively. The regression slopes, shown in Figure 4.3,  
were 0.79 ± 0.04 cm m2/kg and 4.02 ± 0.19 cm3 m2/kg for methods one and two 
respectively (95% CI). 
 
Isolating only the 25 randomly selected patient scans (10 obese, 10 overweight 
and 5 normal BMIs), the R2-value was 0.752 and 0.823, with a regression slope of 0.71 
± 0.09 and 3.82 ± 0.37 cm3 m2/kg for method one and two respectively. Comparatively, 
for method three the R2-value was 0.824, with a regression slope of 80.67 ± 7.76 cm3 
m2/kg  as demonstrated in Figure 4.4. 
 
Figure 4.3. Regression slopes for Method 1 (a) and Method 2 (b). Solid lines = 
regression slope, dotted lines = 95% Confidence Interval 
a b 
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Figure 4.4. Regression slopes for random 25 patients measured with Method 1 (a), 
Method 2 (b), and Method 3 (c).  Solid lines = regression slope, dotted lines = 95% 
Confidence Interval 
 
4.4 INTERFRACTIONAL MOTION  
4.4.1 Inter-user variability measurements 
The variation between the principal investigator and the two research assistants 
in measuring interfractional motion on CBCT was investigated, as detailed in Section 
3.3.1.  
The standard deviation between the 3 users across all matches is summarised in 
Error! Reference source not found..  
a b 
c 
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Figure 4.5. Boxplot of Inter-user Measurements for CBCT.  
4.4.2 Overall Population Results 
The study population as a whole was investigated for interfractional motion 
across the entire course of treatment through descriptive statistics and linear regression 
analysis.  
 
The mean and standard deviation of interfractional motion for all patients over 
the course of treatment in each translation and rotation is detailed in Table 4.7. 
Table 4.7  
Interfractional Mean and Standard deviation across overall study population 
 Mean ± SD 
LR (mm) -0.25 ± 2.01 
AP (mm) -0.53 ± 3.02 
SI (mm) -0.52 ± 3.18 
Pitch (deg) -0.37 ± 4.09 
Yaw (deg) 0.17 ± 1.58 
Roll (deg) 0.35 ± 1.90 
Vector (mm) 5.75 ± 2.25 
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A linear regression on the mean of each translation/rotation for each patient over 
all fractions established that the patient BMI could not statistically significantly predict 
the interfractional motion, as summarised in Table 4.8, except for in the LR translation 
(p= 0.001).  
 
Table 4.8 
Results for Mean Interfractional Linear Regression Analysis 
 R 
Square 
Adjusted R 
Square 
Slope 
Coefficient 
Confidence 
Interval (95%) 
Statistical 
Significance F(1, 130) 
LR (mm) 0.103 0.093 2.204 0.119 to 4.289 7.172, p .001 
AP (mm) 0.009 -0.002 -1.231 -4.460 to 1.998 0.853, p .358 
SI (mm) 0.000 -0.100 -1.001 -4.286 to 2.284 0.002, p .963 
Pitch (deg) 0.007 -0.004 -2.919 -6.857 to 1.018 0.673, p .414 
Yaw (deg) 0.001 -0.010 -0.035 -1.587 to 1.518 0.070, p .792 
Roll (deg) 0.010 -0.001 -0.507 -2.454 to 1.439 0.950, p .332 
Vector (mm) 0.003 -0.008 6.191 4.172 to 8.210 0.250, p .618 
 
4.4.3 BMI Category Results 
Mean Interfractional motion 
A one-way ANOVA was conducted to determine if the mean prostate 
interfractional motion (in LR, AP, SI translations, vector, and Yaw, Pitch and Roll 
rotations) across the entire treatment was different in the different BMI categories. 
Outliers were assessed by a boxplot and the Shapiro-Wilk test (p> .05) indicated 
normally distributed data in all but the mean LR for overweight group (0.044), the 
mean pitch in the overweight group (0.001), the mean roll in the obese group (0.000), 
and the vector in the overweight group (0.000). Due to this non-normal distribution, 
ANOVA was confirmed by performing a Kruskal-Wallis H Test where necessary.  
 
There was homogeneity of variances across the BMI categories, with Levene’s 
test of homogeneity of variance (SI p = 0.515, AP p = 0.992, LR p = 0.065, Vector p 
= 0.791, Yaw p = 0.579, Pitch p = 0.196, Roll p = 0.250). The mean and standard 
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deviations are presented in Table 4.9. There was no statistical significance (p>0.05) 
between any of the translations/rotations except LR (p=0.008) as shown in Table 4.10. 
As the LR in the overweight group was not normally distributed according to the 
Shapiro-Wilk test, a Kruskal-Wallis H test (non-parametric) was performed. This 
confirmed the statistical difference of p=0.008. The plot of the interfractional mean 
LR motion across BMI categories is shown in Figure 4.6.  
 
Tukey post-hoc analysis indicated that the LR difference from 
underweight/normal to obese (-1.353, 95% CI (-2.623 to -.083)) and overweight to 
obese (-1.219, 95% CI (-2.262 to -.176)) was statistically significant (p = 0.031 and 
0.018 respectively).  
 
Table 4.9 
Mean and Standard deviation of the interfractional motion across BMI categories 
Interfractional motion BMI Mean ± SD 
Mean AP (mm) Underweight & Normal -0.18 ± 3.14 
Overweight -1.42 ± 2.87 
Obese 0.16  ± 3.17 
Mean SI  (mm) Underweight & Normal 0.50 ± 3.50 
Overweight -1.53 ± 3.19 
Obese -0.1 ± 2.96 
Mean LR  (mm) Underweight & Normal 0.35 ± 1.79 
Overweight 0.17 ± 1.69 
Obese -1.03 ± 2.24 
Mean Pitch (deg) 
Underweight & Normal 0.19 ± 4.84 
Overweight -0.90 ± 4.27 
Obese 0.09 ± 3.26 
Mean Yaw (deg) 
Underweight & Normal -0.18 ± 1.55 
Overweight 0.06 ± 1.50 
Obese 0.47 ± 1.70 
Mean Roll (deg) 
Underweight & Normal 0.02 ± 1.79 
Overweight 0.50 ± 1.48 
Obese 0.42 ± 2.33 
Mean Vector  (mm) 
Underweight & Normal 5.91 ± 1.59 
Overweight 5.44 ± 2.52 
Obese 5.92 ± 2.22 
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Table 4.10 
One way ANOVA for Mean Interfractional motion 
 ANOVA 
LR (mm) F(2, 130) = 5.041, p = .008 
AP (mm) F(2, 130) = 2.538, p = .084 
SI (mm) F(2, 130) = 3.138, p = .048 
Pitch (deg) F(2, 130) = 0.579, p = .562 
Yaw (deg) F(2, 130) = 1.148, p = .322 
Roll (deg) F(2, 130) = 0.502, p = .607 
Vector (mm) F(2, 130) = 0.731, p = .484 
 
 
 
Figure 4.6. Interfractional total mean LR motion across BMI categories 
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4.5 INTRAFRACTIONAL MOTION  
4.5.1 Inter- & Intra-user variability measurements 
The variation between the principal investigator and 20 radiation therapist staff 
in measuring intrafractional motion on movie captures was investigated, as detailed in 
Section 3.3.2.  
 
The standard deviation across all matches was 0.55 mm, 0.45 mm and 1.46 
degrees in the horizontal, vertical and rotational planes respectively. Table 4.11 shows 
that the principal investigator’s standard deviation was 0.44 mm, 0.38 mm and 0.73 
degrees in the horizontal, vertical and rotational planes respectively. Figure 4.7 
demonstrates these box plots. 
 
 
Table 4.11 
Standard Deviation of Measured Inter-user & Intra-user variability 
 SD overall  
(Inter- & Intra-) 
SD for PI  
(Intra-) 
Horizontal (mm) 0.55 0.44 
Vertical (mm) 0.45 0.38 
Rotation (degrees) 1.46 0.73 
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Figure 4.7. Boxplot of Inter-user Measurements (mm for Horizontal and Vertical, 
Degrees for Rotation). 
 
4.5.2 Overall Population Results 
The study population as a whole was investigated for intrafractional motion 
across the entire course of treatment through descriptive statistics and linear regression 
analysis.  
The mean and standard deviation of intrafractional motion in each translation 
and rotation is detailed in Table 4.12. 
 
Table 4.12  
Intrafractional Mean and Standard deviation across overall study population 
 Mean ± SD 
LR (mm) 0.37 ± 0.83 
AP (mm) 0.34 ± 1.48 
SI (mm) -0.90 ± 1.41 
Pitch (deg) -1.55 ± 5.38 
Yaw (deg) -0.28 ± 1.93 
 
A linear regression established that the patient BMI could not statistically 
significantly predict mean intrafractional motion except for in left-right translation and 
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pitch, as summarised in Table 4.13. A linear regression on the standard deviations of 
intrafractional motion revealed that only superior-inferior was statistically significant 
(p = 0.008), as summarised in Table 4.14. 
 
Table 4.13 
Results for Mean Intrafractional Linear Regression Analysis 
 
 R 
Square 
Adjusted R 
Square 
Slope 
Coefficient 
Confidence 
Interval (95%) 
Statistical 
Significance 
F(1,130) 
LR 
(mm) 
0.032 0.024 0.029 0.0 to 0.057 3.945, p 0.049 
AP 
(mm) 
0.033 0.025 0.049 0.001 to 0.098 4.155, p 0.440 
SI 
(mm) 
0.000 -0.008 0.007 -0.038 to 0.052 0.050 , p 0.823 
Pitch 
(deg) 
0.053 0.045 0.225 0.053 to 0.396 6.756, p 0.011 
Yaw 
(deg) 
0.000 -0.008 0.007 -0.061 to 0.074 0.040, p 0.841 
 
 
 
 
 
Table 4.14 
Results for Standard Deviation Intrafractional Linear Regression Analysis 
 
 R 
Square 
Adjusted R 
Square 
Slope 
Coefficient 
Confidence 
Interval (95%) 
Statistical 
Significance 
F(1,130) 
LR 
(mm) 
0.002 -0.006 0.003 -0.008 to 0.013 2.64, p 0.608 
AP 
(mm) 
0.023 0.015 -0.019 -0.040 to 0.003 2.836, p 0.095 
SI 
(mm) 
0.057 0.049 -0.026 -0.046 to -0.007 7.227 , p 0.008 
Pitch 
(deg) 
0.016 0.008 -0.07 -0.115 to 0.02 1.922, p 0.168 
Yaw 
(deg) 
0.030 0.022 -0.024 -0.049 to 0.001 3.628, p 0.059 
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4.5.3 BMI Category Results 
Mean of intrafractional motion 
A one-way ANOVA was conducted to determine if the mean prostate 
intrafraction motion (in LR, AP and SI translations, and Yaw and Pitch rotations) 
across the entire treatment was different in the each of the BMI categories.  
 
Outliers were assessed by a boxplot and the Shapiro-Wilk test (p> 0.05) 
indicated normally distributed data. There was homogeneity of variances, with 
Levene’s test of homogeneity of variance in all translations/directions except for Pitch 
(AP p = 0.927, SI p = 0.085, LR p = 0.855, Yaw p = 0.588, Pitch p = 0.013). Due to 
this violation of homogeneity of variances for pitch, the Welch’s ANOVA is reported, 
and Games-Howell post-hoc analysis was performed.  The mean and standard 
deviations are presented in Table 4.15.  
 
 
Table 4.15  
Mean and Standard Deviation of Intrafraction motion for the BMI Categories 
Intrafraction motion BMI Mean ± SD 
Mean AP (mm) Underweight & Normal 0.31 ± 1.51 
Overweight 0.19 ± 1.59 
Obese 0.49 ± 1.38 
Mean SI  (mm) Underweight & Normal -1.34 ± 2.10 
Overweight -0.73 ± 1.08 
Obese -1.02 ± 1.12 
Mean LR  (mm) Underweight & Normal 0.35 ± 0.79 
Overweight 0.11± 0.76 
Obese 0.68 ± 0.86 
Mean Pitch (deg) 
Underweight & Normal -2.06 ± 7.14 
Overweight -2.49 ± 5.16 
Obese 0.11 ± 3.58 
Mean Yaw (deg) 
Underweight & Normal -0.18 ± 2.15 
Overweight -0.55 ± 1.87 
Obese -0.07 ± 1.87 
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Table 4.16.  
One way ANOVA for Intrafractional motion 
 ANOVA 
LR (mm) F(2, 130) = 6.126, p = 0.003 
AP (mm) F(2, 130) = 0.743, p =0 .478 
SI (mm) F(2, 130) = 2.045, p = 0.134 
Pitch (deg) F(2, 130) = 5.364, p = 0.007 
Yaw (deg) F(2, 130) = 0.787, p = 0.458 
 
There was no statistical significance (p>0.05) between any of the 
translations/rotations across BMI categories except LR (p=0.003) and Pitch (p=0.007), 
as summarised in Table 4.16. Tukey HSD post-hoc analysis indicated that the LR 
difference from overweight to obese (0.575, 95% CI (0.185 to 0.965)) was statistically 
significant (p = .002). Games-Howell post-hoc analysis indicated that the pitch 
difference from overweight to obese (2.921, 95% CI (0.739 to 5.102)) was statistically 
significant (p = .005). The plot for the intrafractional mean motion is shown in Figure 
4.8 for LR and Figure 4.9 for pitch. 
 
 
Figure 4.8. Intrafractional total mean LR motion across BMI categories 
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Figure 4.9. Intrafractional total mean pitch motion across BMI categories.  
 
Range of intrafractional motion 
The range of motion for each fraction for each patient was investigated by 
subtracting each fraction’s minimum from the maximum displacement.  This is 
visually displayed in the overlayed scatterplots of Figure 4.10 and Figure 4.11. While 
it is evident that a majority of treatments were within PTV margins, there are fractions 
where the range is outside of the margin.  
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Figure 4.10. Overlayed scatterplots of range of motion measured in each 
translation/rotation for the lateral aspects as a function of BMI 
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Figure 4.11. Overlayed scatterplots of range of motion measured in each 
translation/rotation for the anterior aspects as a function of BMI 
 
Frequency of  Displacement 
The frequency of the occurrence of displacement was investigated with the 
percentage of how often a patient’s displacement was within 3 mm, 5 mm and 10 mm 
for translations, and 5, 10 and 20 degrees for rotations calculated by counting the 
number of frames within each given margin. 
 
Table 4.17 represents the range for the overall population and then stratified into 
each BMI category. Figure 4.12 presents these frequencies in boxplot graphs.  
 
To enable further analysis on the anterior/posterior motion and its relationship to QOL, 
the anterior and posterior motion frequencies were calculated separately and is 
represented in Table 4.18 and Figure 4.13. 
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Table 4.17 
Frequency of translations and rotations within given margins, per fraction 
 
Overall Population Underweight/Normal Overweight Obese 
Mean±SD 
(%) 
Min 
(%) 
Max 
(%) 
Mean±SD 
(%) 
Min 
(%) 
Max 
(%) 
Mean±SD 
(%) 
Min 
(%) 
Max 
(%) 
Mean±SD 
(%) 
Min 
(%) 
Max 
(%) 
AP 
≤10mm 99.5 ± 2.0 89 100 99.6 ± 1.0 96 100 99.3 ± 2.0 89 100 99.6 ± 1.0 92 100 
≤5mm 94.4 ± 9.0 45 100 94.6 ± 7.0 76 100 93.1 ± 11.4 45 100 95.7 ± 7.5 78 100 
≤3mm 81.6 ± 16.0 27 100 79.9 ± 17.8 39 100 81.5 ± 18.2 27 100 82.4 ± 13.3 52 100 
SI 
≤10mm 99.6 ± 2.0 78 100 98.4 ± 4.7 78 100 99.8 ± 0.4 98 100 99.9 ± 0.07 100 100 
≤5mm 95.7 ± 1.0 21 100 91.4 ± 16.9 21 100 96.9 ± 6.6 60 100 96.7 ± 6.2 65 100 
≤3mm 83.4 ± 17.0 12 100 75.4 ± 22.9 12 99 86.3 ± 22.9 33 100 84.3 ± 15.7 21 100 
LR 
≤10mm 100 100 100 100 100 100 100 100 100 100 100 100 
≤5mm 99.5 ± 2.0 99 100 99.8 ± 7.3 97 100 99.5 ± 1.7 91 100 99.4 ± 2.1 90 100 
≤3mm 95.9 ± 7.0 62 100 96.8 ± 7.3 74 100 96.3 ± 5.8 73 100 94.7 ± 9.0 62 100 
Pitch 
≤20deg 97.9 ± 7.0 43 100 96.1 ± 9.3 59 100 97.6 ± 8.2 43 100 99.4 ± 2.0 90 100 
≤10deg 86.8 ± 20.0 15 100 78.9 ± 27.3 15 100 86.0 ± 18.9 16 100 91.9 ± 13.6 37 100 
≤5deg 63.9 ± 26.0 2 100 54.9 ± 31.2 3 96 61.6 ± 24.5 2 100 71.6 ± 23.2 10 99 
Yaw 
≤20deg 100 100 100 100 100 100 100 100 100 100 100 100 
≤10deg 99.7 ± 2.0 81 100 99.9 ± 0.6 97 100 99.6 ± 2.7 81 100 99.7 ± 1.9 88 100 
≤5deg 94.3 ± 12.0 32 100 91.4 ± 16.2 32 100 94.1 ± 11.7 49 100 96.3 ± 10.5 38 100 
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Table 4.18 
Frequency of anterior and posterior motions 
 
Overall Population Underweight/Normal Overweight Obese 
Mean±SD 
(%) 
Min 
(%) 
Max 
(%) 
Mean±SD 
(%) 
Min 
(%) 
Max 
(%) 
Mean±SD 
(%) 
Min 
(%) 
Max 
(%) 
Mean±SD 
(%) 
Min 
(%) 
Max 
(%) 
Anterior 
≤10mm 99.9 ± 0.9 92 100 100 100 100 99.7 ± 1.3 92 100 99.9 ± 0.1 99 100 
≤7mm 98.0 ± 4.9 60 100 98.5 ± 4.0 82 100 98.8 ± 4.6 77 100 99.6 ± 1.1 94 100 
≤5mm 96.5 ± 7.7 58 100 95.8 ± 6.9 76 100 96.1 ± 9.6 58 100 97.4 ± 5.3 78 100 
≤3mm 85.2 ± 15.9 26 100 82.3 ± 18 38 100 86.5 ± 16.5 26 100 85.1 ± 14 50 100 
Posterior 
≤10mm 99.4 ± 1.9 88 100 99.4 ± 1.4 94 100 99.3 ± 2.0 88 100 99.5 ± 1.9 89 100 
≤7mm 99.0 ± 3.6 77 100 98.3 ± 3.4 88 100 97.6 ± 6.1 60 100 98.4 ± 4.1 80 100 
≤5mm 95.0 ± 8.7 38 100 95.4 ± 6.7 77 100 93.7 ± 10.4 38 100 96.3 ± 7.3 69 100 
≤3mm 86.9 ± 15.2 19 100 87.2 ± 14.2 50 100 85.2 ± 17.1 19 100 88.5 ± 13.5 50 100 
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Figure 4.12. Boxplots of frequencies for intrafractional translations and rotations 
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Figure 4.13 Boxplots of frequencies for intrafractional anterior motion and posterior 
motion 
 
 
4.6 TOXICITIES  
4.6.1 Overall Population Results 
Of the 92 patients whose whole or partial toxicity data during treatment was 
captured, the overall population mean and standard deviation is summarised in Table 
4.19. Due to the lack of data, no further analysis was conducted for toxicity.  
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Table 4.19  
Overall Population Mean and SD CTCAE scores for treatment weeks 
Toxicity Treatment (Week) 
2 4 6 8 
Fatigue 0.21 ± 0.41 0.21 ± 0.42 0.21 ± 0.42 0.33 ± 0.52 
Weight Gain 0 0 0 0 
Weight Loss 0 0.05 ± 0.22 0 0 
Bloating 0.03 ± 0.17 0.05 ± 0.22 0.05 ± 0.23 0.05 ± 0.22 
Constipation 0.05 ± 0.23 0.03 ± 0.16 0.08 ± 0.28 0.08 ± 0.27 
Diarrhoea 0.03 ± 0.16 0.07 ± 0.26 0.08 ± 0.27 0.19 ± 0.55 
Faecal Incontinence 0 0 0 0.03 ± 0.16 
Flatulence 0 0 0.03 ± 0.16 0.03 ± 0.16 
Haemorrhoids 0 0 0.03 ± 0.16 0.05 ± 0.22 
Nausea 0 0 0 0.03 ± 0.16 
Vomiting 0 0 0 0 
Dehydration 0 0 0 0 
Urinary Frequency 0.56 ± 1.59 0.69 ± 1.35 0.73 ± 1.16 0.71 ± 1.4 
Urinary Incontinence 0.03 ± 0.17 0 0.03 ± 0.16 0.03 ± 0.16 
Urinary retention 0 0 0 0 
Nocturia (No. episodes) 2.67 ± 1.71 3.58 ± 2.3 3.47 ± 1.9 3.8 ± 1.86 
 
4.7 QUALITY OF LIFE 
4.7.1 Overall Population Results 
 
The overall population mean and standard deviations for the QOL standardised 
scores are summarised in Table 4.20 for baseline, treatment and follow-up.  
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Table 4.20.  
Overall Population Mean and SD for EORTC QOL Standardised scores for Baseline, treatment and follow up time frames. *Sexual Functioning and Incontinence were filled 
out only if applicable, with number of responders notated in brackets.  
 
 Base Treatment (Week) Follow Up (Months) 
QOL Domain 2 4 6 8 3  6  12  
Global Health Status 69.24 ± 20.78 74.51 ± 17.31 73.87 ± 19.84 74.23 ± 18.77 74.54 ± 18.84 71.95 ± 20.23 74.06 ± 16.88 73.92 ± 22.64 
F
u
n
ct
io
n
in
g
 
Physical 86.59 ± 14.40 87.64 ± 14.65 89.29 ± 13.02  88.79 ± 15.59 89.04 ± 15.46 85.57 ±  16.35 83.85 ± 17.37 82.44 ± 19.30 
Role 85.71 ± 22.16 88.36 ± 21.67 87.50 ± 19.95 87.36 ± 20.92 85.90 ± 21.88 85.24 ± 25.67 82.13 ± 25.94 80.90 ± 25.82 
Emotional 83.72 ±  16.86  87.39 ± 15.78 89.62 ± 14.94 89.74 ± 16.39 88.62 ± 18.07 85.98 ± 19.23 86.72 ± 18.20 85.33 ± 16.87 
Cognitive 83.14 ±   20.76 87.28 ±  16.04 87.08 ±  15.65 88.75 ±  17.35 86.76 ±  18.42 84.75 ±  17.08 85.22 ±  17.49 84.88 ±  15.97 
Social 86.05 ±   23.55 87.83 ±   20.03 89.12 ±   19.33 89.37 ±   18.31 90.63 ±   19.19 86.16 ±   22.12 85.42 ±   21.66 82.64 ±   25.70 
S
ym
p
to
m
 S
co
re
 
Fatigue 24.62 ±   23.00 20.27 ±   18.00 21.48 ±   19.87 23.47 ±   20.34 22.75 ±   19.96 27.20 ±   25.27 25.46 ±   20.77 27.43 ±   19.07 
Nausea  2.75 ±   7.56 1.58 ±   4.90 2.08 ±   6.32 1.72 ±   5.55 1.56 ±   4.87 3.49 ±   9.99 2.92 ±   8.34 3.55 ±   8.42 
Pain 12.55  ±   21.21 8.70  ± 17.01    8.54  ± 16.79    11.06  ±   17.58 9.31  ± 14.38    11.64  ±   20.21 10.76  ±   19.64 11.68  ±   20.29 
Dyspnoea 14.49 ± 20.56 11.49 ± 18.70 11.57 ± 18.61 12.25 ± 19.38 13.02 ± 20.41 15.72 ± 23.55 17.69 ± 25.42 18.21 ± 24.07 
Insomnia 26.74 ± 30.32 23.28 ± 28.22 25.28 ± 30.56 23.65 ± 28.05 23.05 ± 30.17 23.90 ± 28.64 27.55 ± 28.73 24.74 ± 28.17 
Appetite 4.44 ± 14.31 5.46 ± 15.19 4.17 ± 12.65 5.46 ± 15.19 5.66 ± 16.89 6.03 ± 16.53 7.48 ± 16.94 8.59 ± 18.81 
Constipation 13.92 ± 22.26 6.03 ± 16.80 7.50 ± 17.53 8.83 ± 19.77 12.15 ± 23.52 6.92 ± 17.65 6.53 ± 15.69 8.93 ± 19.55 
Diarrhoea 6.37 ± 16.57 11.01 ± 20.10 15.13 ± 20.70 15.10 ± 20.29 15.89 ± 20.14 8.25 ± 15.87 7.56 ± 15.59 10.07 ± 18.81 
Financial Diff 11.99 ± 24.23 14.78 ± 25.05 13.33 ± 26.43 14.37 ± 26.82 14.33 ± 25.54 12.89 ± 29.30 10.65 ± 22.33 11.46 ± 22.60 
Sexual Activity 81.76 ± 26.05 83.97 ± 21.92 87.65 ± 17.56 87.65 ± 19.78 87.80 ± 20.77 88.72 ± 19.02 88.64 ± 17.55 86.96 ± 19.74 
Urinary 19.58 ± 14.04 19.10 ± 14.65 24.81 ± 16.63 26.57 ± 16.82 27.21 ± 17.96 16.41 ± 13.71 15.91 ± 14.36 17.77 ± 15.02 
Bowel 4.53 ± 6.59 4.09 ± 6.63 5.96 ± 8.14 7.95 ± 11.42 7.25 ± 9.22 5.53 ± 7.66 5.99 ± 8.88 8.24 ± 12.93 
Hormone Related 13.64 ± 12.14 11.70 ± 10.72 10.75 ± 10.56 11.58 ± 13.04 11.64 ± 12.44 14.63 ± 13.00 15.34 ± 12.21 16.36 ± 15.11 
Sexual 
Functioning* 
66.67 ± 29.52 
(12) 
66.27 ± 18.91 
(21)  
70.24 ± 20.60 
(14) 
71.88 ± 16.02 
(8) 
68.45 ± 18.54 
(14) 
59.52 ± 26.32 
(14) 
62.22 ± 24.97 
(15) 
53.89 ± 28.32 
(15) 
Incontinence* 8.33 ± 16.67     
(4) 
16.67 ± 19.25   
(4) 
19.05 ± 26.23   
(7) 
16.67 ± 18.26 
(6) 
18.18 ± 27.34 
(11)  
22.22 ± 17.21   
(6) 
13.33 ± 23.31 
(10) 
11.11 ± 17.21   
(6)  
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4.7.2 BMI Category Results 
Mean of QOL scores 
A one-way ANOVA was conducted to determine if the change in QOL scores 
from baseline to 12 month follow up was different between BMI categories.  
 
Outliers were assessed by boxplot, and the Shapiro-Wilk test (p> 0.05) indicated 
normally distributed data. There was homogeneity of variances, with Levene’s test of 
homogeneity of variance in all score changes except for Hormone Related symptom 
score change (p=0.037). Due to this violation of homogeneity of variances for 
Hormone Related symptom score change, the Welch’s ANOVA is reported.  
Table 4.21 
One way ANOVA for QOL score changes *Sexual Functioning and Incontinence were filled out only 
if applicable 
QOL Domain ANOVA 
Global Health Status F(2, 125) = 1.882, p = .157 
F
u
n
ct
io
n
in
g
 Physical F(2, 125) = 1.417, p = .246 
Role F(2, 125) = 1.578, p = .211 
Emotional F(2, 125) = 1.141, p = .323 
Cognitive F(2, 125) = 0.296, p = .744 
Social F(2, 125) = 1.258, p = .288 
S
ym
p
to
m
 S
co
re
 
Fatigue F(2, 125) = 0.602, p = .549 
Nausea  F(2, 125) = 0.114, p = .892 
Pain F(2, 125) = 0.304, p = .739 
Dyspnoea F(2, 125) = 0.942, p = .392 
Insomnia F(2, 125) = 0.145, p = .865 
Appetite F(2, 125) = 1.391, p = .253 
Constipation F(2, 125) = 0.371, p = .691 
Diarrhoea F(2, 125) = 2.726, p = .069 
Financial 
Difficulties 
F(2, 125) = 2.147, p = .121 
Sexual Activity F(2, 125) = 0.158, p = .854 
Sexual Functioning* F(2, 39) = 0.312, p = .734 
Urinary F(2, 125) = 0.329, p = .721 
Bowel F(2, 125) = 0.093, p = .911 
Hormone Related F(2, 125) = 1.844, p = .166 
Incontinence* F(2, 24) = 0.120, p = .888 
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There was no statistical significance (p>0.05) between any of the changes in 
QOL scores across the different domains, for BMI categories, as summarised in Table 
4.21.  
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Chapter 5: Discussion 
This chapter discusses the findings of the study, including: 
 Patient Specifics 
 BMI and Pelvic Adiposity 
 Inter- and Intra-user variability 
 Interfractional Motion 
 Intrafractional Motion 
 QOL 
And 
 Future Directions for Study 
 
5.1 PATIENT ACCRUAL & SPECIFICS  
Patient accrual was much lower then initially anticpated, as demonstrated in 
Figure 4.1. This early close to accrual is acknowledged as a limitation of the study, 
and reduced power to 0.72 from 0.8.  The lower accrual was due to an unforseen 
decline in referrals to the centre for EBRT during early recruitment stages. The reason 
for this is considered to be two-fold:  
1.  A new radiation therapy centre opened up in the TCC catchment area, 
meaning that patients from that area received treatment at the new centre rather then 
being referred to TCC 
2. The low dose brachytherapy program within Townsville increased its service 
capacity, reducing referrals for EBRT.  
 
As eligible patients were approached consecutively, regardless of BMI, it was 
important to establish that the BMI range within the study population represents the 
wider population, without an over-representation of any BMI category. The patient 
population evaluated closely represents the Australian and Queensland male BMI 
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proportions reported in 2013 (Australian Health Survey : Updated Results, 2013), as 
shown in Table 5.1. 
 
5.2 BMI & PELVIC ADIPOSITY 
The strong regression between BMI and pelvic adiposity measured with both 
methods validates the continued use of BMI as a measure of pelvic adiposity. As 
research continues into the effect of obesity and adiposity on the treatment of prostate 
cancer, particularly with radiation therapy, this is an important validation. Not only 
does this have relevance in the radiation oncology setting, but other health areas where 
a similar patient population is seen, such as orthopaedics.  
 
Table 5.1 
Comparison of BMI proportions to Australian Bureau of Statistics proportions for Australian Male 
population and Queensland Male population  
  
Underweight 
(%) 
Normal 
(%) 
Overweight 
(%) 
Obese 
(%) 
T
h
is
 S
tu
d
y
 
All ages 
(Median 
71 
years) 
0.8 18.5 43.1 37.7 
A
u
st
ra
li
a
n
 
R
es
u
lt
s 
45-54 0.7* 20.8 45.1 33.4 
55-64 0.3* 21.1 40.6 37.9 
65-74 0.2** 19.2 46.3 34.3 
75-84 np np 48.9 23.6 
85+ np np 44.7 *16.0 
Q
u
ee
n
sl
a
n
d
 
R
es
u
lt
s 
45-54 19.2 47.1 33.7 
55-64 15.8 37.1 47.1 
65-74 14.3 46.9 38.8 
75-84 18.4 np np 
85+ 35.9* np np 
* estimate has a relative standard error of 25% to 50% and should be used with caution; ** 
estimate has a relative standard error greater than 50% and is considered too unreliable for general use; 
np not available for publication but included in totals where applicable, unless otherwise indicated 
(Australian Health Survey : Updated Results, 2013).  
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5.3 INTER- AND INTRA-USER VARIABILITY 
The inter-user variability of both the CBCTs and the movie captures was within 
IGRT action levels for the translational measurements with a maximum standard 
deviation of 0.55 mm. There was more variability in the standard deviation of the 
rotational measurements at 1.46 degrees for the inter-user group, and 0.73 degrees for 
the principal investigator for intrafractional data, and a maximum of 0.09 degrees (in 
pitch) for the interfractional data. The difference in rotational standard deviations 
between the inter- and intra-fractional data is most probably explained by the 
differences in the process of matching between 2D and 3D datasets.  There are three 
dimensions of the CBCT for the inter-fractional data to match to, compared to only 
matching in the one plane of the movie capture for the intra-fractional data. The 
additional planes of the CBCT give more information for the best fit.  Rotation 
variablitiy becomes particularly important when the more irregular shapes of prostate 
+ SV PTVs are being treated. Some variation in the rotation on a more spherical shape 
(prostate only) does not have the same degree of clinical significance as an irregular 
shape (prostate + SV).  The greater the rotation of an irregular shape, the greater the 
potential for geometric miss, and this can be compounded through inter-user 
differences in image matching. However, as the inter-user rotation was less than 1.5 
degrees, the clinical impact is minimal.  
 
The nature of the “best fit” method for aligning the fiducial markers on both the 
CBCTs and the movie captures allows for some subjectivity. A greater degree of 
deformation was noted to result in a greater degree of subjectivity in the best fit match. 
This subjectvity could be further investigated by measuring points placed centrally in 
the visible markers on both CBCTs and movie captures and recording the coordinates 
of these points. This would be possible by exporting the CBCTs and loading them in 
the XiO planning system. There is currently no capability for determining coordinates 
on iView, therefore an additional software system would be required, which was 
beyond the scope of this project. 
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5.4 INTERFRACTIONAL MOTION 
It has been demonstrated and is widely accepted that the external skin marks, 
such as tattoos which are used to set up a prostate patient do not correlate to the position 
of the prostate (O’Daniel, Dong, & Zhang, 2006). The inference, therefore, is that the 
larger the patient, the greater the mobility of the skin marks.  
 
5.4.1 Overall Population Results  
Wong et al., (2008) measured interfractional motion on pre-treatment CT-on-
rails scans of 329 patients. Frank et al., (2008) measured interfractional motion on CT-
on-rails scans performed three times a week for 15 IMRT patients. Comparing the 
results of the overall population mean and standard deviations to both of these studies 
shows no inconsistencies (Table 5.2). However it should be noted that in both of these 
studies measured  using a soft-tissue prostate IGRT matches, and it was not detailed 
how the match was performed where significant rotation was present (e.g. best fit 
match). No account of rotational displacement or how this may have affected matching 
(such as applying “best-fit”) was described (Frank et al., 2008; Wong et al., 2008). 
Table 5.2 
Comparison of Mean and Standard Deviation Interfractional Results  
 Mean ± SD (mm) 
This Study Wong et al 
(2008) 
Frank et al 
(2008) 
LR (mm) -0.25 ± 2.01 0.9 ± 3.7 -0.2 ± 0.9 
AP (mm) -0.53 ± 3.02 0.4 ± 5.5 0.1 ± 4.1 
SI (mm) -0.52 ± 3.18 0 ± 2.6 0.5 ± 2.9 
Pitch (deg) -0.37 ± 4.09 NR NR 
Yaw (deg) 0.17 ± 1.58 NR NR 
Roll (deg) 0.35 ± 1.90 NR NR 
Vector (mm) 5.75 ± 2.25 NR 4.6 ± 3.5 
(NR = Not reported) 
 
5.4.2 BMI Category Results 
The hypothesis that BMI influences interfractional motion was not supported by 
the results, except for in the LR translations. In both linear regression analysis and one-
way ANOVA of the mean interfractional motion, a statistically significant relationship 
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was only found in the LR direction (p = 0.001 and 0.008 for regression and ANOVA 
respectively). There was a difference found in LR motion between the 
underweight/normal and the obese categories (p= 0.031), and the overweight and 
obese category (p= 0.018). However, in evaluating the mean and standard deviations 
(Table 4.9) and the mean LR interfractional motion plot (Figure 4.6), it is noted that 
there is a tendency for the obese patient group to be offset more to the right (-1.027 ± 
2.235) than the underweight/normal and overweight groups (0.349 ± 1.787 and 0.168 
± 1.690 respectively).  This is not considered to be of clinical significance, as there is 
no reason for treatment staff to expect that an obese patient be more offset to the right 
of the bed. One consideration was if patients tended to get on to the treatment couch 
on one side there may be potential LR bias. However the patients in this study were 
treated over 3 different linacs with different room configurations, in which on two 
linacs the majority of patients tend to get onto the couch from their left side, and on 
the other linac the majority of patients tend to get onto the couch from their right side. 
While this may be a contributing factor, data was not collected to substantiate this.  
 
Our results support that of Wong et al., (2009) who likewise found that a 
statistically significant relationship between patient BMI and LR standard deviation 
shift (p < 0.01) through Pearson’s correlation analysis, however, only magnitude, not 
direction (that is, left or right) is reported. 
 
 
5.5 INTRAFRACTIONAL MOTION 
The main hypothesis was that there was a relationship between interfractional 
motion and patient’s BMI, which was not supported by our findings.  
 
5.5.1 Overall Population Results 
 
The results indicated translational means and standard deviations well within 
current PTV margins, however the limitations of considering only mean and standard 
deviations are discussed further in “Range and Frequency”. A standard deviation of 
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5.38 degrees for pitch reflects a greater range in this rotation, a key finding of this 
study.  
 
Using electromagnetic transponders, Butler et al (2012) investigated the effect 
of BMI on prostate displacement. Their overall results based on 66 patients (Mean 
BMI = 28.7 ± 4.2 kg/m2) are compared to this study in Table 5.3, again, showing no 
inconsistencies. It should be noted that the patients were treated in a prone position 
with a custom thermoplastic hip-fix immobilizer over the buttocks and abdomen for 
treatment. A larger intrafractional motion in the prone position has been reported, 
compared to the supine (p < 0.0001) (Kitamura et al., 2002), with respiratory motion 
affecting prostate motion more in the prone position (Shah et al., 2011). 
 
Table 5.3 
Comparison of Mean and Standard Deviation Intrafractional Results 
 Mean ± SD 
This Study Butler et al 
(2012)* 
LR (mm) 0.37 ± 0.83 0.56 ± 0.24 
AP (mm) 0.34 ± 1.48 1.15 ± 0.30 
SI (mm) -0.90 ± 1.41 1.16 ± 0.37 
Pitch (deg) -1.55 ± 5.38 NR 
Yaw (deg) -0.28 ± 1.93 NR 
*Treated in prone position; NR = Not Reported 
 
5.5.2 BMI Category Results 
Mean and Standard Deviation 
The hypothesis that BMI influences intrafractional motion was not supported by 
the results. The linear regression analysis did not find any statistical significant 
relationship and thus BMI could not predict the intrafractional motion. In one-way 
ANOVA, both LR translational motion and Pitch rotational motion showed statistical 
significance (p = 0.003 and p = 0.007 respectively). The statistically significant 
difference was between the overweight and obese groups for both LR and Pitch 
(p=0.002 and p=0.005 respectively). In examining the mean and standard deviations, 
and means plots, there is a tendency for the obese patient to be offset more to the left. 
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This is in direct contrast to the interfractional tendency for obese patients to be offset 
more to the right. It is hypothesised that there may be systematic displacement in the 
setup of a patient which is being over-corrected for on CBCT imaging, and once the 
patient settles and relaxes during treatment, the prostate drifts back. This could be 
tested through setting the patient up and waiting 1-2 minutes before acquiring the 
CBCT image, and comparing the results. In overweight patients, there was a tendency 
for more pitch rotation when compared to the obese patients, with rotation towards the 
posterior.  
 
The standard deviation findings are supported by those of Thompson et al., 
(2011), as compared in Table 5.4. 
 
Their conclusion was that while there was no statistical significance in the 
intrafractional difference between BMI categories, there may be greater stability of the 
prostate in the larger BMI patients, once isocentre correction has been made 
(Thompson et al., 2011). Indeed, the standard deviations of patients >35 kg/m2 were 
within 2mm in all translational directions, however it should also be noted that there 
were only 8 patients with a BMI of >35kg/m2. Comparatively, our study had 21 
patients with BMIs >35kg/m2 and we did not find this trend, except for the LR 
direction.  
 
 
Table 5.4 
Comparison of Standard Deviation intrafractional linear regression findings  
 
 Slope 
Coefficient 
Confidence Interval 
(95%) 
p value 
T
h
is
 s
tu
d
y
 
L
R
 
(m
m
) 
0.003 -0.008 to 0.013 0.608 
A
P
 
(m
m
) 
-0.019 -0.040 to 0.003 0.095 
SI 
(mm) 
-0.026 -0.046 to -0.007 0.008 
T
h
o
m p
s
o
n
 
A
L
 
et
 
a
l LR 
(mm) 
-0.006 -0.020 to 0.008 0.37 
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AP 
(mm) 
-0.02 -0.040 to 0.000 0.056 
SI 
(mm) 
-0.02 -0.037 to -0.003 0.023 
 
 
 
In separating the overall study population to low BMI (<30 kg/m2) and high BMI 
(≥30 kg/m2), no significant difference in the standard deviation of the translational 
motions or vector between the two groups was found, with treatment in the prone 
position (Butler et al., 2012).  
 
Range & Frequency 
While the mean intrafractional motion is an important indicator of motion, more 
extreme motions within a fraction, such as the sudden transient motion described in 
Section 2.3.2, will not be reflected in the mean. This occurs when there are 
approximately as many motions in a positive direction as there are in a negative 
direction. To investigate cases of more extreme motion, both the range of motion, and 
the frequency of displacement within 3 mm, 5 mm and 10 mm were analysed.  
 
Current margins on CTV for the PTV are 10mm in LR, SI and anterior 
directions, and 5-7mm in the posterior direction. Previous studies in margin reduction 
to as little as to 3mm have been performed (Melancon et al., 2007; Mutanga et al., 
2011).  
When examining the overall population, the percentage of the intrafractional 
motion within 3 mm was 81.6 ± 16.0 and 83.4 ± 17.0 for the AP and SI translations 
respectively. This agrees closely with the findings of Nichol et al., (2010) where 
motions of greater than 3mm were observed in 12% of the total measurements 
(measuring every 9 seconds over 9 minutes total time on MRI scans).   
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5.5.3 Limitations 
Movie Capture Methodology 
As already discussed in Section 3.7.2, a limitation of the movie capture method 
for measuring the intrafractional motion is that only one aspect can be captured at any 
given time. This means that translation for any given field can only be assessed in two 
dimensions and any motion in the third, unmeasured dimension for that field would 
not be detected. Similarly, only one type of rotation would be measured per image. For 
example, while measuring a lateral aspect, no motion in the left-right direction would 
have been detected. Additionally, only every second frame was analysed. A major 
limitation of the movie capture methodology is the lack of real-time data – that is, only 
one aspect with its relevant displacements (as summarised in Table 5.5) can be 
collected and measured at any given time.  
 
Table 5.5 
Translations and Rotations Measured from each aspect 
Aspect Translations Measured Rotation Measured 
Laterals/Posterior 
Obliques 
Superior-Inferior 
Anterior-Posterior 
Pitch 
 
Anterior Left-Right 
Superior-Inferior 
Yaw 
 
 
Within our department, the treatment is standardly delivered from left to right, 
that is, the left lateral/oblique is delivered first, and the right lateral/oblique is delivered 
last. Because the greatest motion is expected in the dimensions captured by the lateral 
aspects, by treating and capturing these two aspects first and last meant that the overall 
drift in these directions can be gathered from the right aspect, with some sudden 
transient motion captured in the individual aspects.  
 
At present, there is no method utilising conventional linac technology which allows 
for more than the 2D information captured in the movie captures. The combination of 
MV and kV fluoroscopy has been investigated for intrafraction prostate monitoring 
(Adamson & Wu, 2008, 2010; Ng et al., 2012) however this introduces additional dose. 
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Adamson & Wu, 2008 report an additional dose of 4.6cGy per fraction, with two 
CBCTs and seven fluoroscopies taken with the bowtie filter and Ng et al., (2012) report 
an additional 61mSv at 10 Hz.  Comparatively, electromagnetics beacons do not 
require additional dose, but require significant capital and on-going costs compared 
with current FM techniques, as detailed in 2.2.5.  
 
While real-time information would be ideal, the movie capture methodology 
nevertheless allowed for adequate measurements to indicate intrafraction motion, 
particularly of drifting motion. It is acknowledged however, that some motion, 
particularly sudden transient motion, may have not been captured in the assessed 
movie loops and therefore it is possible not all intrafraction motion has been reported. 
While this limitation is acknowledged, there is enough data measured to adequately 
answer the research question. Additionally, any undetected sudden transient motion is 
of limited clinical significance as only a very small dose would have been delivered 
during the time of the transient prostate displacement.  
 
Possibility of Slight Patient Movement from CBCT Couch Shift 
It is not possible to quantify how much the patient or the patient’s organs may 
move between acquisition of the CBCT and the delivery of the first treatment field (for 
example, due to movement of the patient independently of the treatment couch as it 
moves into the corrected position) as discussed in Section 3.4.6. Therefore, the 
difference between the initial CBCT displacement and that of the first aspect captured 
may be due to the patient moving slightly, factors such as peristalsis, or a combination 
of these.  
 
5.5.4 Rectal Motion 
During data measurement, it was observed that the anterior motion was most 
often due to rectal gas (and to a lesser extent, faecal matter) at the prostate level 
displacing the prostate anteriorly. With the inconsistencies in diameter and shape of 
the rectum at the prostate level, rectal dose can also be increased with superior or 
inferior motion, particularly if this motion moves the prostate to a place of greater 
rectal diameter.  
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The inconsistencies with diameter and shape of the rectum observed supports the 
case for replicating the degree of rectal filling as closely as possible to the planning 
scan, and the careful scrutiny of daily treatment imaging such as CBCT for differences 
in the rectal diameter/shape. This is supported by the finding of Adamson and Wu 
(2009) that rectal filling status on a day-to-day basis is a significant predictor (p 
<0.001) of prostate motion, with patients with a consistent gas volume of >0.5cm3 
showing greater motion (p = 0.028) (Adamson & Wu, 2009).  
 
One might expect that as rectal toxicities increase in the latter half of treatment, 
the intrafraction motion may be affected by this, particularly if toxicities such as 
diarrhoea affect the amount of rectal gas and/or faecal matter present. The data 
gathered in this study could be analysed further to determine if this is the case.  
 
5.5.5 Bladder Motion 
The state of bladder filling affects the intrafractional motion to a lesser extent 
than the rectum. Natural bladder filling occurs at an average rate of <10 ml/min and 
generally fills in the superior direction (Homma et al., 2003). Therefore in the 7-10 
minutes it takes to deliver treatment after verification imaging, it is not expected to 
greatly displace the prostate. If departments were implementing longer treatment times 
such as hypofractionated schemes, the bladder filling during delivery may be of greater 
concern.  
 
The bladder filling during treatment is likely to affect the position/shape of the 
seminal vesicles more than the prostate itself, however this is beyond the scope of this 
study (Frank et al., 2008).  
 
5.5.6 Rotation  
One of the greatest challenges remains rotation, particularly in pitch which is 
influenced largely by rectal volume differences. Bowel protocols minimise these rectal 
differences, however if the patient has an acceptable rectal diameter on planning scan, 
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a small difference in rectal diameter at treatment can produce a large difference in 
rotation.  
 
Rotation was evident in our results, with pitch consistently greater than 5 degrees in 
over half of all fractions in 34 patients. Eleven patients had pitch greater than 10 
degrees in over half of all fractions. In two extreme cases, one patient had greater than 
20 degrees of pitch for 57% of all treatments, and another for 41%. Both of these 
patients had SVs included in the PTV for a partial course.  
 
While IGRT strategies allow for the ease of translational corrections, there are 
currently limited actions for the correction of rotational displacements. Current 
treatment couch tops with 6 degrees of freedom capabilities (such as Hexapod) allow 
for the correction of limited degrees. Our results indicate that in the pitch rotation, 
63.9% of all treatments were under 5 degrees. The Hexapod system available in our 
department can correct for rotations of up to three degrees, and therefore the use of 
this would be beneficial for smaller rotations, however would not allow correction of 
some of the larger rotations measured.   
 
One of the greatest causes of prostate rotation and deformation is gas or faecal 
matter content of the rectum, particularly at the level of the prostate. A distended 
rectum can cause significant rotation, predominately in pitch.  
 
Pitch rotation is of particular concern if the SVs are within the PTV. As the 
prostate is vaguely spherical in shape, when treating prostate only, rotational error has 
limited possibility of underdosing the PTV. However, the addition of SVs within the 
PTV creates a much more irregularly-shaped PTV, increasing the possible clinical 
significance of rotational errors. This rotation is represented in simple diagrammatic 
form in Figure 5.1.  
 
Current protocol is for bowel preparation to occur over the patient’s treatment 
course, however it is evident from these results that these are not adequate in achieving 
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consistency with rectal gas/faecal contents. Indeed, anecdotally, some patients report 
more bloating, irregularity or diarrhoea with Movicol. Further departmental 
investigations into bladder and bowel preparation have been and continue to be 
undertaken.  
 
It was anecdotally noted that differences in rectal gas/faecal matter content at the 
prostate level affected rotation and displacement. However, to quantify the rectal 
distention and/or shape changes was beyond the scope of this project.  
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Figure 5.1 A typical left lateral field for prostate only (mauve with blue PTV) (a-i) 
and prostate with SVs (yellow with cyan PTV) (b-i). A-ii shows a simple 
diagrammatic field of prostate only, and b-ii showing prostate + SVs. A-iii and b-iii 
shows the same field with the PTVs rotated by 10 degrees, and a-iv and b-iv shows 
15 degrees.  
a-i 
a-ii 
a-iii 
a-iv 
b-i 
b-ii 
b-iii 
b-iv 
ant ant post post 
sup sup 
inf inf 
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5.5.7 Number of Fiducial Markers 
Without the triangulation of three visible markers, the measurement of rotations is 
potentially less accurate or impossible (Kudchadker et al., 2009). At the time of 
protocol development, the loss of one or more markers was not deemed to be 
actionable (i.e. excluding patient from further study). While utilising the one or two 
markers is preferable to no markers at all, it does introduce another potential source of 
error.  
 
5.6 TOXICITY 
5.6.1 Limitation 
The large amounts of missing data makes interpretation of these results difficult, 
and thus analysis was restricted to overall population results. Of note is the increase of 
diarrhoea toxicity scoring from 0.03 ± 0.16 to 0.19 ± 0.55, and urinary frequency from 
0.56 ± 1.59 to 0.71 ± 1.4 at week 2 of treatment to week 8 of treatment, however the 
standard deviations indicate large population variance. Another compounding factor 
is the scores were recorded by a number of Radiation Oncologists or Radiation 
Oncology registrars, and this was not stratified for. Not stratifiying the scorings may 
introduce some variance.  
 
5.7 QOL 
 There was no significant relationship between BMI and intrafractional motion, 
and therefore it was not expected for there to be a significant relationship between BMI 
and QOL. Indeed, no statistical difference between the QOL scores for the different 
BMI categories was found (Table 4.21).  
 
5.7.1 Comparison of Data 
Overall population mean and standard deviations are compared to published data 
for functional scores in Table 5.6, and symptom scores in Table 5.7. It should be noted 
that for the global health status and the functional scores, a higher score indicates a 
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high QOL and high level of functioning. For the symptom scores, a higher score 
indicates a higher level of symptoms, and thus a lower QOL (Fayers et al., 2001). 
 
The EORTC reference data provides baseline data for all stages and all ages 
collected from 3,361 patients (Fayers et al., 2001). Our results are similar, with higher 
scores in functional domains. Similarly, symptom scores are similar with some 
noticeable exceptions such as pain and appetite where our scores are lower, and 
probably more reflective of the fact the reference data includes all stages of prostate 
cancer.  
 
Van Andel et al., (2008) collected QOL PR-25 prostate module responses from 
418 patients at baseline and 3-month follow up. Three different subgroups were 
collected: surgery; EBRT; and EBRT + hormonal therapy. Unfortunately the QOL 
data presented does not stratify these, and by comparing this study results, we are 
comparing EBRT +/- hormonal therapy to the 3 different subgroups as a whole. Of 
note is the much higher sexual activity within our population for both baseline and 3 
month follow up responses, however this is difficult to confidently compare as sexual 
function and activity, characterised mostly by erectile dysfunction, is documented to 
be worse after surgery (Gore et al., 2010; Mols et al., 2009).   
 
Table 5.6 
Comparison of QLQ-C30 QOL data to EORTC Reference Data 
QOL Domain Baseline 
This Study EORTC Ref 
(2008) 
Global Health Status 69.24 ± 20.78 68.4 ± 22.2 
F
u
n
ct
io
n
i
n
g
 
Physical 86.59 ± 14.40 80.2 ± 25.6 
Role 85.71 ± 22.16 82.7 ± 28.2 
Emotional 83.72 ±  16.86  76.6 ± 23.0 
Cognitive 83.14 ±   20.76 83.2 ± 20.8 
Social 86.05 ±   23.55 80.2 ± 27.2 
S
ym
p
to
m
 S
co
re
 
Fatigue 24.62 ±   23.00 26.9 ± 26.6 
Nausea  2.75 ±   7.56 5.1 ± 14.2 
Pain 12.55  ±   21.21 23.3 ± 30.3 
Dyspnoea 14.49 ± 20.56 16.8 ± 25.7 
Insomnia 26.74 ± 30.32 24.5 ± 30.5 
Appetite 4.44 ± 14.31 10.4 ± 23.6 
Constipation 13.92 ± 22.26 14.6 ± 27.2 
Diarrhoea 6.37 ± 16.57 8.4 ± 19.4 
Financial Diff 11.99 ± 24.23 9 ± 21.5 
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Table 5.7 
Comparison of PR-25 Data to Published Data 
QOL Domain Baseline 3 month follow up 
This Study Van Andel et al 
(2008) 
This Study 
 
Van Andel et al 
(2008) 
S
ym
p
to
m
 S
co
re
 
Sexual Activity 81.76 ± 26.05 37.4 ± 27.6 88.72 ± 19.02 27.8 ± 26.0 
Urinary 19.58 ± 14.04 16.5 ± 16.3 16.41 ± 13.71 22.7 ± 18.1 
Bowel 4.53 ± 6.59 4.5 ± 8.6 5.53 ± 7.66 5.4 ± 9.4 
Hormone Related 13.64 ± 12.14 6.9 ± 9.1 14.63 ± 13.00 11.9 ± 10.7 
Sexual 
Functioning* 
66.67 ± 29.52 
(12/130 = 9.2%) 
75 ± 21.4 
(304/472=64.4%) 
59.52 ± 26.32 
(14/130 = 
10.8%) 
53.6 ± 25.4 
(194/463=41.9%
) 
Incontinence* 8.33 ± 16.67     
(4/130 = 3.1%) 
10.6 ± 26.3 
(41/472=8.7%) 22.22 ± 17.21   
(6/130 = 4.6%) 
22.6 ± 27.1 
(146/463=31.5%
) 
 
 
5.7.2 Limitations 
Due to the negative health effects associated with higher BMI, it is expected that 
patients with higher BMIs may have more severe and/or a greater number of co-
morbidities such as diabetes and high blood pressure. While this is somewhat captured 
in the baseline QOL, each patient’s co-morbidities were not collated or analysed.  
 
5.8 FUTURE DIRECTIONS 
This study highlights future directions for further study into the concern of 
intrafractional motion.  
 
5.8.1 Adaptive XRT 
An emerging theme arising from the data was that of adaptive XRT through the 
prediction of motion. Current department protocol for PTV definition is a uniform 
expansion of the CTV except in the posterior direction where 5-7 mm is utilised. The 
CTV encompasses the whole prostate, and seminal vesicles are included where there 
is risk of seminal vesicle involvement.  
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Adaptive regimens may include generating a new PTV based from the 
compilation of a number of CTVs defined on initial treatment CBCTs (3 to 5 fractions) 
for the remainder of the treatment course. The idea behind this is that utilising the 
initial CBCTs will capture the individual patient’s standard motion and any 
deformation present on those initial treatment fractions. While the ability to predict 
motion based on initial motion monitoring was not explored in this study, it could be 
retrospectively analysed.  
 
 
5.8.2 Undefined Daily Rectal and Bladder Volume Parameters 
Currently there are no clear departmental guidelines on when to intervene based 
on varying bowel and bladder volumes evident on the pre-treatment CBCT, as 
previously described in Section 2.2.4.   
 
Actions such as getting the patient off the treatment couch to release gas before 
continuing with treatment delivery are somewhat subjective, and may be dependent 
upon the clinical judgment of the treatment staff. This will occur when so much gas is 
present that it causes severe prostate deformation, and an acceptable “best match” is 
not achievable. If, however, an acceptable fiducial match is able to be made and the 
gas is causing only significant displacement which can be corrected for, there is 
ambiguity as to whether to continue with treatment or not.  
 
Defining the upper and lower limits acceptable in both bladder and bowel 
content will provide clear action thresholds for when to continue with treatment and 
when to intervene to minimise intrafractional motion.  
 
5.8.3 Models Predicting Motion 
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Rectal Influences 
Using the data collected in this study, investigations are being undertaken into 
the feasibility of predicting the prostate motion based on the measurement of the rectal 
gas/faecal content on the patient’s pre-treatment CBCT.  
 
Bladder Influences 
As mentioned in Section 2.3.2, the influence of bladder filling was beyond the 
scope of this project however, the data collected may be utilised to investigate this 
further.  
Bladder filling influences may be retrospectively analysed through the 
contouring of both bladder and seminal vesicles on the daily CBCTs and assessing for 
relationship between bladder volume and seminal vesicle displacement. This however 
would prove a challenge as: 
 The quality of the CBCTs makes delineation of the seminal vesicles 
difficult in most cases (as seen in Figure 2.3) 
 As a small field of view is utilised to minimise dose and centred at the 
isocentre (most often on the prostate), all of the bladder volume may not 
be captured in the CBCT FOV. However, quantifications of the base of 
bladder and its effect on the SVs may be possible.  
 
5.8.4 QOL 
While not pertinent to the aims and objectives of this study, valuable data has been 
collected through the QOL forms. Further analysis, particularly into the social and 
emotional themes emerging from the QOL, will be of interest but is of no relevance to 
the patient’s BMI influencing motion.  
 
5.8.5 Disease Free Survival 
It will be of interest to retrospectively examine this patient population’s disease 
free survival, particularly in terms of those patients who had larger intrafraction 
motion, and larger pitch rotations. 
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Our two key findings were: 
1. There is no clinically significant relationship between patient BMI and 
prostate motion. 
2. Rotational displacements remain one of the greatest challenges in the 
accurate delivery of radiation therapy to the prostate.  
 
This study did not find any significant relationship between patient BMI and 
interfractional prostate motion, except for the LR direction (p = 0.001) where the mean 
LR motion was -1.027 ± 2.235 mm for obese patients, compared to 0.349 ± 1.787 and 
0.168 ± 1.690 mm for underweight/normal and overweight patient respectively. For 
intrafractional motion, a significant relationship was only found in LR and pitch in 
intrafractional motion (p = 0.003 and 0.007 respectively), where the mean LR motion 
was 0.683 ± 0.856 mm for obese patients, compared to 0.352 ± 0.790 and 0.108 ± 
0.760 mm for underweight/normal and overweight patient respectively; and the mean 
pitch motion was 0.105 ± 3.583 degrees for obese patients, compared to -2.055 ± 7.139 
and -2.488 ± 5.159 degrees for underweight/normal and overweight patient 
respectively .    
 
While the findings do not support the hypothesis that inter- and intra-fractional 
prostate displacement correlates significantly with the patient’s BMI in EBRT of 
prostate cancer, they support the ever-growing body of evidence that highlights the 
importance of daily IGRT strategies. This is of particular significance in the 
advancements of radiation therapy treatment of the prostate, including IMRT, VMAT 
and hypo-fractionated schedules.  
 
Our rotational results indicate the importance of correction for significant 
rotation, particularly pitch. The higher standard deviation in pitch when compared to 
the other rotations across the overall population is of note. This is highlighted by 
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individuals who had significant pitch for at least half of their treatment (34 patients 
(26.2%) consistently ≥ 5 degrees, 11 patients (8.5%) consistently ≥ 10 degrees). This 
remains a great challenge in the EBRT for prostate cancer. These findings highlight 
the necessity for adherence to bladder and bowel protocol, and for the development of 
guidelines to inform the treatment therapists to take decisive action should there be 
considerable bladder/rectum volume changes on a daily basis.  
 
The value of accessing not only motion but toxicity and QOL should not be 
underestimated. While no relationship between BMI and QOL was found, the QOL 
data collected is of great importance, and provides a benchmark for future technologies 
and techniques introduced within our department in the future.  
 
In the continuing improvement of radiation therapy for prostate cancer, IGRT must 
continue to play an integral part. Advancements in the monitoring and correction of 
intrafractional motion will allow for safer dose escalation with the potential for 
reduced side effects, and improved quality of life.   
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